Molecular basis for the lipid raft recruitment of NK cell receptors and development of a sialic acid-based Siglec-7 inhibitor by Gütgemann, Stephan Alexander
Dissertation  
submitted to the 
 Combined Faculties for the Natural Sciences and for 
Mathematics of the Ruperto-Carola University of 
Heidelberg, Germany 
 for the degree of  
Doctor of Natural Sciences 
 
 
 
 
 
 
 
 
presented by 
Master of Science in Biology Stephan Alexander Gütgemann 
born in:  Bonn, Germany  
Oral-examination:  
  
  
Molecular basis for the lipid raft 
recruitment of NK cell receptors and 
development of a sialic acid-based 
Siglec-7 inhibitor 
 
 
 
 
 
 
 
 
 
 
 
 
Referees:  Prof. Dr. Walter Nickel 
Prof. Dr. Carsten Watzl 
 
  
“He who asks a question is a fool for 5 minutes;  
he who does not ask a question remains a fool forever.“ 
 
 
- Ancient Chinese Proverb - 
  
 
  
Table of Contents 
 
TABLE OF CONTENTS .............................................................................................. 7	  
ACKNOWLEDGEMENTS ........................................................................................... 9	  
SUMMARY ................................................................................................................ 11	  
ZUSAMMENFASSUNG ............................................................................................ 12	  
1	   INTRODUCTION ................................................................................................. 13	  
1.1	   NATURAL KILLER CELLS .................................................................................. 13	  
1.2	   FUNCTIONS OF NK CELLS ............................................................................... 14	  
1.3	   NK CELL ACTIVATION & INHIBITION .................................................................. 15	  
1.4	   INHIBITORY NK CELL RECEPTORS .................................................................... 16	  
1.4.1	   KIRs ....................................................................................................... 17	  
1.4.2	   CD94/NKG2 ........................................................................................... 18	  
1.4.3	   Other inhibitory receptors ...................................................................... 18	  
1.4.4	   NK cell education ................................................................................... 18	  
1.4.5	   Siglecs ................................................................................................... 19	  
1.5	   ACTIVATING NK CELL RECEPTORS ................................................................... 22	  
1.5.1	   ITAM-signaling receptors ....................................................................... 22	  
1.5.2	   SLAM-related receptors ......................................................................... 22	  
1.5.3	   NKG2D .................................................................................................. 23	  
1.5.4	   CD16 ...................................................................................................... 24	  
1.5.5	   Integrins ................................................................................................. 24	  
1.5.6	   Other activating receptors ...................................................................... 25	  
1.6	   LIPID RAFTS .................................................................................................... 25	  
1.6.1	   Lipid rafts in NK cells ............................................................................. 28	  
1.7	   AIM OF THE THESIS ......................................................................................... 30	  
2	   MATERIALS AND METHODS ............................................................................ 31	  
2.1	   MATERIALS ..................................................................................................... 31	  
2.1.1	   Vectors ................................................................................................... 31	  
2.1.2	   Constructs .............................................................................................. 31	  
2.1.3	   Bacteria .................................................................................................. 32	  
2.1.4	   Cells ....................................................................................................... 32	  
2.1.5	   Reagents ............................................................................................... 34	  
2.1.6	   Inhibitors ................................................................................................ 35	  
2.1.7	   Buffers ................................................................................................... 36	  
2.1.8	   Mouse monoclonal antibodies ............................................................... 37	  
2.1.9	   Secondary antibodies ............................................................................ 38	  
2.1.10	   Recombinant proteins .......................................................................... 38	  
2.1.11	   Enzymes .............................................................................................. 39	  
2.1.12	   Oligonucleotides .................................................................................. 39	  
2.1.13	   Kits ....................................................................................................... 41	  
2.2	   METHODS ....................................................................................................... 42	  
2.2.1	   Molecular biology ................................................................................... 42	  
2.2.2	   Cell biology ............................................................................................ 43	  
2.2.3	   Protein biochemistry .............................................................................. 47	  
3	   RESULTS ............................................................................................................ 49	  
3.1	   MECHANISMS OF LIPID RAFT RECRUITMENT OF NK CELL RECEPTORS ............... 49	  
3.1.1	   Lipid raft recruitment of 2B4 (CD244) .................................................... 49	  
3.1.2	   Lipid raft recruitment of NKG2D ............................................................. 57	  
3.2	   INHIBITION OF SIGLEC-7 BY SIALIC ACID-BASED INHIBITORS .............................. 60	  
3.2.1	   Development of Siglec-7 inhibitor .......................................................... 60	  
3.2.2	   Functional effects of sialic acid-based inhibitor on NK cells .................. 68	  
3.2.3	   Factors influencing Siglec-7 inhibitor efficacy ........................................ 70	  
4	   DISCUSSION ...................................................................................................... 73	  
4.1	   LIPID RAFT RECRUITMENT OF ACTIVATING NK CELL RECEPTORS ....................... 73	  
4.1.1	   Lipid raft recruitment of the SLAM-related receptor 2B4 ....................... 73	  
4.1.2	   Lipid raft recruitment of the C-type lectin-like receptor NKG2D ............. 82	  
4.2	   DEVELOPMENT OF A SIGLEC-7 INHIBITOR ........................................................ 85	  
REFERENCES .......................................................................................................... 90	  
ABBREVIATIONS ................................................................................................... 104	  
 
 
 
 
  
Acknowledgements 
 
First of all I want to thank my supervisor Prof. Dr. Carsten Watzl. Thank you for 
giving me the possibility to do this work in the first place, for your ever-helpful 
guidance and making the lab a nice place to be. Your advice was always available if 
sought and greatly helped me in finishing this work. 
 
I also want to thank Prof. Dr. Walter Nickel for officially representing this work in the 
faculty of biosciences and his support in the organization of this work. 
 
Thanks go to my colleagues, all the members of the (in)famous Watzl lab (past and 
present)! First for the tremendous amount of cake, second for your continuous help, 
creating a pleasant working atmosphere and making me laugh and laugh and 
laugh…. Thanks to you, I learned a vast amount of stuff (not always about science 
but always worth knowing). 
I will dearly miss your company, especially that of: 
 
Stephan ‘Käpt’n’ Meinke 
Doris Urlaub 
André ‘Wingman’ Cohnen 
Maren ‘Klaucs’ Claus 
Christian Schütz 
Petra Netter 
Steffen Killian 
 
Sebastian Stark 
Sabine Wingert 
Martha-Lena Müller 
Mina Sandusky 
Stefanie Margraf 
Wolfgang Merkt 
Birgitta Messmer
I also sincerely want to thank our collaborators Prof. Dr. Brossmer and his ever-
tireless technician Horst Prescher for their interest and contribution to this work. 
Thank you for the inhibitors and your help, both were essential to this work. 
 
Moreover, I want to thank Dr. Martin Frank for permitting me the use of his Siglec-7 
docking models. Your models greatly aided in the understanding of our work. 
Furthermore I want to thank all members of the institute for immunology in 
Heidelberg for their constant and termless support. Whatever was asked for, it was 
given without hesitation. 
 
Special thanks belong to my future wife! Thank you for your ever-lasting support, 
your patience and your love! 
 
I also want to thank my family, especially my parents, my godfather and my siblings 
for motivating me, assisting me and helping me whenever they can.  
 
Last but not least I want to thank my friends, just for being there when it counts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Summary 
The activation status of natural killer (NK) cells is determined by the integration of 
activating and inhibitory signals at the immunological synapse between the NK cell 
and a target cell. In this work we studied the activating and inhibitory signals of NK 
cells: 
The presence of cholesterol-rich membrane domains at the activating immunological 
synapse and the absence of these membrane domains at inhibitory immunological 
synapses has supported the role of lipid rafts in the regulation of NK cell activation. 
Several activating NK cell receptors are known to localize into these lipid rafts upon 
ligation and thereby influence the functional outcome of a NK cell-target cell contact. 
How these receptors are recruited into these important membrane domains remains 
unknown though. In order to elucidate the molecular basis of these mechanisms we 
studied the structural requirements of the human activating NK cell receptors 2B4 
and NKG2D for receptor recruitment into detergent-resistant membrane (DRM) 
fractions as a model for lipid raft association. Structural requirements in 2B4 for DRM 
recruitment could be identified at the luminal side of the transmembrane domain and 
in the CxC motif near the cytoplasmic side of the transmembrane domain. Similar to 
2B4, we could determine a requirement for the NKG2D transmembrane domain for 
DRM recruitment. However, DRM recruitment of both receptors was independent 
from signal transduction. Thus our study presents data about potential molecular 
mechanisms involved in lipid raft recruitment. 
In order to study NK cell inhibition, we developed inhibitors against the sialic acid-
binding receptor Siglec-7 on NK cells. This receptor is known to exert inhibitory 
effects on the function of NK cells and is harnessed by certain pathogens and 
malignancies for immune evasion. The inhibitors were designed by collaborating 
biochemists based on the structure of unmodified sialic acid. We screened a broad 
collection of inhibitors and tested these in functional assays for their capacity to block 
Siglec-7 receptor-ligand interaction and their effect on NK cell activity. In conclusion, 
this collaborative study was able to generate the first inhibitor with high affinity 
against Siglec-7 and with a functional effect on the cytotoxicity of NK cells.  
 
  
Zusammenfassung 
Die Aktivierung von natürlichen Killer (NK)-Zellen resultiert aus der Integration von 
aktivierenden und inhibierenden Signalen an der immunologischen Synapse 
zwischen einer NK-Zelle und einer Zielzelle. Diese Arbeit behandelt diese 
aktivierenden sowie inhibierenden Signale in NK-Zellen: 
Durch die Präsenz von Cholesterin-reichen Membrandomänen in aktivierenden 
Synapsen und die Abwesenheit dieser Membrandomänen in inhibierenden 
Synapsen wurde die Rolle von „Lipid Rafts“ in der Regulation der NK-Zellaktivierung 
gestärkt. Im Falle mehrerer aktivierender NK-Zell-Rezeptoren wurde eine 
Rekrutierung in diese Membrandomänen nach Zielzell-Bindung festgestellt was den 
funktionellen Ausgang solch eines Zellkontaktes maßgeblich beeinflussen kann. Wie 
diese Rezeptoren allerdings in die Membrandomänen rekrutiert werden ist bislang 
nicht bekannt. Um die molekularen Mechanismen für diese Rekrutierung 
aufzudecken haben wir die strukturellen Voraussetzungen für die Rekrutierung der 
NK-Zell-Rezeptoren 2B4 und NKG2D in Detergenz-resistente Membranen (DRM) als 
Model für die „Lipid Raft“-Rekrutierung untersucht. Strukturelle Voraussetzung in 2B4 
für die DRM-Rekrutierung lagen an der luminalen Seite der Transmembrandomäne, 
sowie in einem CxC-Motiv an der zytoplasmatischen Seite der 
Transmembrandomäne. Auch NKG2D war strukturell für eine DRM-Rekrutierung auf 
die Transmembrandomäne angewiesen. Eine Signaltransduktion war jedoch bei 
beiden Rezeptoren nicht involviert. Diese Studie weist damit strukturelle 
Voraussetzungen und potenzielle Mechanismen für die „Lipid Raft“-Rekrutierung von 
Rezeptoren auf. 
Um die NK-Zell Inhibition zu untersuchen wurden Inhibitoren gegen den Sialinsäure-
bindenden Rezeptor Siglec-7 entwickelt. Dieser Rezeptor kann die Zellaktivierung 
von NK-Zellen hemmen und wird durch diverse Pathogene und in verschiedenen 
Krankheiten als Immunevasionsmechanismus missbraucht. Auf der Grundlage von 
unmodifizierter Sialinsäure wurde eine Kollektion von Inhibitoren von 
kollaborierenden Biochemikern entwickelt und von uns in funktionellen Assays auf 
die Fähigkeit die Rezeptor-Ligandenbindung zu blockieren sowie die NK-Zellaktivität 
zu beeinflussen getestet. In dieser gemeinschaftlichen Studie wurde der erste hoch-
affine Siglec-7-Inhibitor mit Einfluss auf die NK-Zellfunktion entwickelt. 
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1 Introduction 
1.1 Natural killer cells 
Natural killer (NK) cells are a subset of lymphocytes belonging to the innate immune 
system of vertebrates and comprise 2-18 % of the lymphocytes in peripheral blood 
[1]. NK cells were first discovered in 1975 and named according to the observed 
function of these cells. The term “natural cytotoxicity” was coined as this population 
of cells performed cytotoxicity without the need for prior sensitization, unlike T or B 
cells [2-5]. Although initially thought to be nonspecific, the activity of NK cells is 
regulated, as was first predicted by the formulation of the “missing self hypothesis” in 
1986 [6]. This notion was supported by the discovery of various inhibitory [7, 8] and 
activating [9-11] receptors on NK cells. These findings implied that unlike other 
lymphocytes like T cells or B cells, NK cells do not express an affinity maturated 
monoclonal antigen receptor on their surface. Instead they express a diverse array of 
germ-line encoded activating and inhibitory receptors [12]. This independence 
enables NK cells to respond faster to an infection than lymphocytes of the adaptive 
immune system as no somatic recombination and clonal expansion is required. Still, 
NK cells expand upon infection and migrate from the blood to the site of infection. In 
fact, NK cells are the major population of immune cells keeping viral infections at bay 
in the first days, until the more specific adaptive immune response can clear the 
infection, if still present [13, 14]. These are the main reasons why NK cells are 
commonly classified into the innate rather than the adaptive immune system. 
Similarities with other lymphocytes remain though, as NK cells originate from the 
same common lymphoid progenitor as T and B cells in the bone marrow. For 
example, NK cells share properties like common lymphoid signal cascades with T 
and B cells. In contrast to T cells, NK cells do not rely on the thymus though [15].  
NK cells are not a population of simple killer cells, but include several subtypes of 
cells and overall fulfill a range of different tasks and functions in the body. Commonly 
described as CD56+CD3- lymphocytes, NK cells nowadays are additionally 
characterized by their expression of NKp46 [16, 17]. Still, this marker set seems to 
be insufficient to completely describe NK cells, as NKp46+ non-NK cells have already 
been described [18, 19]. NK cells are not a homogenous population of NKp46+ 
CD56+ CD3- lymphocytes though. There are two main populations defined by their 
level of CD56 surface expression: CD56dim and CD56bright NK cells. In addition, the 
NK cell population contains plenty of cells with completely different functions: The 
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already mentioned cytotoxic capacity of NK cells residues mostly in the CD56dim 
CD16+ NK cells [20], which is the most prominent NK cell population in peripheral 
blood (about 90% of peripheral blood NK cells). NK cells are also capable producers 
of cytokines like interferon (IFN)-γ, tumor necrosis factor (TNF)-α and granulocyte 
macrophage colony stimulating factor (GM-CSF) [21]. This function resides in the 
CD56bright CD16- NK cells mostly, which are preferentially found in lymph nodes, 
secondary lymphoid tissues and only to a lesser extent in the peripheral blood [22]. 
The functional capacity of these subsets is not exclusive however, and each subset 
is able to perform the other’s main function as well, although to a lesser extent [20]. 
This functional junction makes more sense in view of recent findings, which imply a 
developmental link between those subsets, and state that the CD56bright NK cells are 
the less mature NK cells and eventually develop into CD56dim NK cells [23, 24]. Other 
specialized subsets of NK cells with different functions were also found in the gut, the 
lung, the liver and the uterus [18, 25-27].  
1.2 Functions of NK cells 
The most prominent function of NK cells is their ability to lyse sensitive target cells, in 
most cases virally infected cells or transformed cells [28, 29]. NK cells are also 
involved in immune responses against other intracellular pathogens [30, 31]. A lack 
of NK cells or their functions has been shown to cause increased sensitivity towards 
infections and transformed cells [32]. Especially in the early course of an infection NK 
cells play a major role in protection, while the adaptive immune response is still 
developing [12, 21]. Once a contact between NK cell and target cell is established 
and an immunological synapse (IS) has formed, the NK cell gauges the target cell for 
its sensitivity. Whether or not a target cell is sensitive is defined by its expressed 
ligands for activating and inhibitory receptors that are described in more detail later 
on. If a target cell is sensitive, a NK cell possesses two different mechanisms to kill it: 
The first is the lysis by cytotoxic granules released upon the target cell in the IS. 
These granules contain different effector molecules like perforin, granzymes and 
granulysin, which interfere with the membrane integrity of the target cell and induce 
apoptosis e.g. by activation of the caspase cascades [33, 34]. Apart from this 
mechanism, NK cells also express ligands for so-called death receptors, like Fas-
receptor or TRAIL receptor, and can trigger these receptors on the target cell, again 
resulting in apoptosis induction [34]. One has to keep in mind though that NK cells 
are not completely independent from adaptive immune responses, as e.g. NK cells 
can recognize bound antibodies with a Fc receptor and mediate killing of antibody-
coated target cells, a process called antibody-dependent cellular cytotoxicity (ADCC) 
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[9]. These mechanisms are used to kill infected and/or transformed cells, but NK 
cells also harbor different links to adaptive immunity: It has previously been shown 
that NK cells are able to modulate immune responses, either by secretion of 
cytokines or by killing other immune cells. For example, TH cells can be skewed 
toward a TH1 response by the IFN-γ produced by NK cells [35]. On the other hand, a 
bidirectional influence between NK cells and dendritic cells (DCs) has been 
described: NK cells can activate DCs and are stimulated by DCs in return, but can kill 
immature DCs as well [36, 37]. These interactions can modulate the adaptive 
immune system; either by boosting an immune response by activating DCs, or a 
potential harmful immune response (e.g. against a self-antigen) can be prevented by 
killing immature DCs in the right place [36]. Another protective role against 
autoimmune pathologies has emerged in the last years: NK cells are able to 
recognize the activation status of macrophages [38] and eventually remove them. If 
this control is absent, hyperactivated cells could cause harm in the body, which is the 
case in certain kinds of hemophagocytic lymphohistiocytosis. A deficiency in perforin 
secretion, which abolishes the cytotoxic potential of NK cells, can result in the 
occurrence of hyperactivated macrophages and T cells that cause severe harm via 
different mechanisms [39-41]. 
Other functions of NK cell subsets or NK cell-related subsets include the control of 
mucosal homeostasis in mucosa-associated lymphoid tissues as well as regulation of 
angiogenesis in the decidua during pregnancy [18, 19, 42]. 
1.3 NK cell activation & inhibition 
The recognition of target cells by NK cells, independent whether they are infected, 
transformed or hyperactivated, relies on the integration of signals from activating and 
inhibitory receptors. Both, activating and inhibitory receptors are present on NK cells 
in a vast array of different receptors in order to enable the NK cell to gauge the target 
cell by different means. In a first step the NK cell makes contact with its target cell, 
which involves the binding of adhesion molecules on the target cell by the NK cell 
integrins. This ligation of adhesion molecules induces first signals resulting in 
cytoskeletal reorganization at the contact site [43, 44]. During the establishment of a 
contact site an immunological structure is formed between the two cells: the IS. The 
IS is ordered and can be observed in different contacts of immune cells, but was first 
observed for T cells and antigen presenting cells [45]. Based on the original 
observation from T cells, the activating IS has been proposed to be divided into three 
distinct concentric rings: the central supramolecular activation cluster (cSMAC) 
contains the signaling receptors and eventually the degranulation site of the cytotoxic 
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granules. The cSMAC is surrounded by the peripheral SMAC (pSMAC) formed by 
adhesion molecules, like integrins, which tightly segregate the cSMAC from the 
outside. The pSMAC is encircled by the distal SMAC (dSMAC) that encloses the IS 
[45, 46]. Once contact is established, the NK cell gauges the target cell with its 
receptors by integrating activating and inhibitory signals, either resulting in activation 
or inhibition. An activating signal of one receptor is not enough to trigger resting NK 
cells, with the exception of the Fc receptor CD16, instead a combination of signals 
from different receptors is required to activate the NK cell. Most of the activating NK 
cell receptors are able to synergize in order to cross the required activation threshold 
[47, 48]. This led to the notion to call all NK cell receptors, except CD16, ‘co-
activating receptors’. Although NK cells are regarded as natural killers, an activation, 
e.g. by cytokines as IL-2 or IL-15, can lower this threshold to the level that the 
triggering of a single receptor is sufficient to activate the NK cells [48]. 
An activating signal causes a series of consecutive steps: An activating NK cell 
immune synapse (aNKIS) is established in an actin-dependent way and activating 
receptors are recruited into the IS together with lipid raft clustering in the synapse 
[45, 49]. Meanwhile, the microtubule-organizing center (MTOC) is reoriented towards 
the target cell. The cytotoxic granules are then polarized towards the target cell and 
their content is released upon the target in the synaptic cleft. Dominating inhibitory 
signals, in contrast, cause the formation of an inhibitory NK cell immune synapse 
(iNKIS), which is structurally distinct from the aNKIS [50]. This leads to a 
dephosphorylation of Vav-1, the essential guanine nucleotide exchange factor (GEF) 
for the small GTPase Rac1, which is crucial for actin remodeling and subsequent 
steps [51, 52]. This abolishes actin remodeling, receptor clustering and lipid raft 
clustering in the IS [45]. A dephosphorylation of Vav-1 thus causes an early block of 
signaling by activating receptors. This process is independent of the cytoskeleton 
and finally causes the NK cell to spare the target cell [52]. 
1.4 Inhibitory NK cell receptors 
Since the formulation of the “missing self hypothesis” it has been clear that certain 
receptors on NK cells must be able to inhibit a cytotoxic response against target cells 
[6]. Several different groups of inhibitory receptors have been described on NK cells. 
The majority of these receptors recognize MHC class I molecules, but there are 
some receptors as well that recognize non-MHC ligands. These ligands can be 
influenced by cytokines, stress, viral infection or transformation and thus give a 
status of the target cell. For example, certain viruses cause a reduction of MHC class 
I molecules on the cell surface of infected cells in order to evade T cell responses 
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[53]. At the same time this decreases the inhibition of NK cells towards them by 
reducing inhibitory ligands, making them more susceptible for NK cell mediated lysis. 
Even inhibitory receptors are not structurally related in all species, their function is 
the same. All of them share the presence of immunoreceptor tyrosine-based 
inhibition motifs (ITIMs) or related signaling motifs in their cytoplasmic domain.  
 
Figure 1: Simplified model of NK cell inhibition. A range of inhibitory receptors expressed on the NK cell 
surface recognizes diverse ligands on the target cell upon contact. Most inhibitory NK cell receptors (like 
Killer cell Immunoglobulin-like receptors or KIRs) recognize MHC class I molecules or related 
molecules, but some receptors recognize MHC-independent ligands, e.g. glycoconjugates as 
recognized by Siglec receptors. Upon ligation an inhibitory receptor is phosphorylated and recruits 
phosphatases (like SHP-1) that mediate downstream inhibition by dephosphorylating key substrates of 
activating signal pathways. 
The common mechanism includes the phosphorylation of the ITIM followed by the 
subsequent recruitment of phosphatases like the protein tyrosine phosphatases 
SHP-1 and SHP-2 or the inositol-5-phosphatase SHIP-1 [54]. These phosphatases 
then abolish activating signals by dephosphorylating key substrates like Vav-1 [52]. A 
simplified model is depicted in Figure 1. 
1.4.1 KIRs 
The main group of inhibitory receptors on human NK cells is formed by the killer cell 
immunoglobulin-like receptors (KIRs), which recognize HLA molecules on the 
surface of target cells [55]. KIRs contain either two or three extracellular Ig-like 
domains and either a long cytoplasmic tail containing an ITIM or a short cytoplasmic 
tail without the ITIM. The ITIM-containing KIRs belong to the inhibitory receptors 
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whereas the KIRs without an ITIM associate with ‘DNAX-activating protein of 12 kDa’ 
(Dap12) and belong to the activating receptors [56, 57]. The extracellular domains 
are highly homologous in activating and inhibitory KIRs. The exact reason for this 
high homology between activating and inhibitory KIRs is still unknown. The functional 
homologues of the KIRs in the mouse are the Ly49 receptors, which belong to the C-
type lectin-like receptors and are therefore structurally unrelated to the KIRs [58]. As 
with the KIRs, the Ly49 receptors bind MHC class I molecules and contain inhibitory 
as well as activating members. 
1.4.2 CD94/NKG2 
Another receptor group consists of the heterodimer of the lectin-like CD94 and 
members of the C-type lectin-like NKG2 family of receptors [59]. As with the KIRs, 
this receptor family contains activating and inhibitory receptors. The most important 
inhibitory receptor out of this group, CD94/NKG2A, recognizes the non-classical HLA 
allele HLA-E. HLA-E presents the leader peptides of other MHC class I molecules 
and thereby presents a range of MHC class I-derived ligands [60].  
1.4.3 Other inhibitory receptors 
The third group of MHC class I binding inhibitory receptors is formed by the leukocyte 
Ig-like receptors (LILRs) which are expressed on NK cells and recognize different 
HLA alleles [61]. 
Apart from these MHC class I recognizing receptors, NK cells also express a variety 
of receptors which have non-MHC ligands [54]: For example, the receptor NKR-P1 
recognizes CLEC2D [62], LAIR-1 binds collagen [63, 64] and KLRG1 binds 
cadherins [65]. Even more inhibitory receptors with completely different ligand 
specificities are expressed enabling NK cells to gauge target cell condition through 
different means [54].  
 
1.4.4 NK cell education 
Receptors of the KIR and CD94/NKG2 family are randomly expressed on NK cells 
[66]. This phenomenon can lead to the occurrence of NK cells devoid of inhibitory 
receptors or at least inhibitory receptors able to recognize abundant self-MHC alleles 
[67]. In contrast, this could also lead to NK cells that have several functional 
inhibitory self-receptors. The lack of any inhibition together with the potential to 
recognize activating ligands should lead to autoreactivity of these NK cells against 
healthy cells. The apprehended autoreactivity of NK cells without inhibitory self-
ligands does not occur though. NK cells which are unable to recognize inhibitory 
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ligands are hyporesponsive [68]. A process of education of maturing NK cells has 
been proposed, but the exact mechanism still remains unknown: One model states 
that NK cells may be stimulated by default, but enter the state of 
hyporesponsiveness without an occasional inhibitory signal [69]. In contrast, another 
model assumes that NK cells remain hyporesponsive until they are “licensed” by 
inhibitory signals resulting in responsive NK cells [70, 71]. The view of this education 
was changed when it was shown that the regulation of NK cells does not occur in a 
digital “on-off” modulation as an increasing amount of inhibitory self-ligands resulted 
in NK cells of higher responsiveness [72]. This observation led to the formulation of 
the Rheostat model, which can be applied to both previous education models [73]. 
This model states that the responsiveness of NK cells is tuned by a continuum that is 
defined by the amount of inhibitory input in the NK cells education. Thus, an NK cell 
without an inhibitory input becomes hyporesponsive whereas an NK cell with strong 
inhibitory input (e.g. through several KIRs) becomes very responsive. The 
hyporesponsive NK cells have been shown to be of importance despite their 
functional deficiency though: In a murine cytomegalovirus model it was shown that 
the actual immune response was dependent on the hyporesponsive NK cells. These 
hyporesponsive NK cells can regain function in this situation, which might be due to 
the completely absent inhibition of these cells [74]. Additionally, recent studies imply 
that the effect of education on the responsiveness of an NK cells is reversible and 
can change in a new environment [75]. Further research has to be performed to 
unravel this important issue. 
1.4.5 Siglecs 
An interesting group of sialic acid-binding lectin receptors is also present on NK cells 
[76]: Sialic acids are nine-carbon sugars derivatized from neuraminic acid via N- or 
O-substitution and are commonly attached to the non-reducing end of extracellular 
glycoconjugates, e.g. gangliosides [77, 78]. These sialosides have different 
functional roles and are involved in physiological, pathophysiological and 
pathological mechanisms. For example, the influenza virus uses sialic acids to bind 
to target cells via hemagglutinin (HA) and induces production of sialidase after 
infection in order to render the cell resistant to other viral particles [79]. The lectin 
family of proteins has evolved to recognize glycosylations and consists of several 
subgroups: The C-type lectins (e.g. selectins), the S-type lectins (Galectins) and the 
I-type (or, as members of the Ig-superfamily, Ig-like) lectins. The best-studied group 
of I-type lectins is classified as the sialic acid-binding Ig-like lectins (Siglecs) family 
and consists of 16 known members in humans [80]. These receptors are again 
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subgrouped into the conserved group 1 found in all mammals and the rapidly 
evolving CD33-related Siglecs, which show immense differences between species 
[80-82]. With two exceptions (Siglec-4 and Siglec-6), all Siglecs are expressed in the 
hematopoietic system and play an important role in the regulation of immune cells 
[83]. The Siglec receptors share features in structure: All receptors are type I 
transmembrane proteins and contain an amino-terminal V-set Ig-domain and a 
variable number of C2-set Ig-domains followed by a transmembrane domain [83]. 
The cytoplasmic part of the proteins differs in the conserved group 1 of Siglecs, but 
most of the CD33-related Siglecs harbor an ITIM proximal to the transmembrane 
domain followed by an ITIM-like motif [83]. These motifs are able to recruit protein 
tyrosine phosphatases such as SHP-1 and SHP-2 [83] and show inhibitory effects on 
the function and proliferation of cells, if the receptors are triggered [84, 85]. In 
contrast to other sialic acid-binding lectins, the ligand recognition of Siglecs by the V-
set Ig-domain is not only based on the negative charge of the ligand, but it was 
shown that the ligand interacts through several specific interactions with the receptor 
[82, 86]. One crucial interaction common to Siglecs is the formation of a salt bridge 
between an arginine in the receptor and the carboxylate of the sialic acid [86, 87]. 
Though the ligand specificity is higher than in other I-type lectins, the binding affinity 
of Siglecs towards their ligands is low and binding relies on avidity [83]. The CD33-
related Siglecs mainly differ in their V-set Ig-domain and thus in their specificity 
towards differently linked sialic acids. Usually, Siglec receptors are masked by cis 
interactions with sialic acids, but can be unmasked upon sialidase treatment or by 
cell activation [88]. 
On NK cells, the expression of three members of the Siglec family was shown, all 
belonging to the CD33-related group: Siglec-3 (or CD33) [89], Siglec-7 (CD328) [87, 
90, 91] and Siglec-9 (CD329) [92-94]. CD33 contains only one C2-set Ig-domain and 
is partially expressed on NK cells as an isoform without V-set Ig-domain, which thus 
does not possess sialic acid-binding capacity [89]. Siglec-7 and Siglec-9 both contain 
a V-set Ig-domain and two C2-set Ig-domains. They are similar in structure in over 
80%, but differ in their ligand specificity [92-95]. In addition, Siglec-7 is the major 
Siglec receptor abundant on NK cells, whereas it is also present on a subset of CD8+ 
T cells, to a lower extent on monocytes and at low levels on granulocytes [91]. Sialic 
acid specificities of these Siglecs vary as shown in Figure 2 [83]. Whereas Siglec-7 
has an unusually high affinity for α2,8-disialyl residues and binds well to branched 
α2,6-sialyl residues, Siglec-9 (and Siglec-3 to a lesser extent) binds well to terminal 
α2,3- and α2,6-sialyl residues [83, 95, 96].  
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Figure 2: Specificities of NK cell expressed Siglec receptors. Specificities for the most common sialic 
acid residues and their linkages are displayed for the three NK cell Siglec receptors. The degree of 
specificity ranges from (-) no specificity, (+) low specificity, (++) moderate specificity and (+++) high 
specificity. Specificity data were adopted from studies employing glycoprobes to screen Siglec 
specificities [95, 96]. 
 
The best-studied Siglec expressed on NK cells is Siglec-7, which was investigated in 
structure [97-101] and function [102] in detail; however, much remains to be 
unraveled still. The α2,8-disialyl residues recognized by Siglec-7 are especially 
abundant on a group of gangliosides as GD3, GD1b and GT1b, also called the “b-
series” gangliosides [78, 103]. Functional implications for ganglioside expression 
have been shown in several studies: For example, the expression of the ganglioside 
GD3 on P815 cells modulated the lysis mediated by NK cells [104] and the DSGb5 
ganglioside (branched α2,6-disialic) on renal cell carcinoma cells also decreased the 
NK cell-mediated lysis [105]. The ‘b-series’ gangliosides are present in neuronal 
tissues [78] where such inhibitory interactions with Siglec receptors could prevent 
autoreactivity [106]. In addition, GD3 has been shown to be expressed strongly in 
melanomas [107], which might imply an immunoevasion mechanism applied by 
cancer cells. But Siglec-7 has also been shown to be involved in viral and bacterial 
control: HIV infection was shown to be associated with the appearance of Siglec-7-
deficient NK cell subpopulations which can be used as progression markers of the 
disease [108, 109]. In addition, bacteria have been shown to acquire Siglec ligands 
in order to modify the host-pathogen interaction [110, 111]. 
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1.5 Activating NK cell receptors 
All NK cells express a range of different activating receptors granting them the ability 
to screen target cells for their respective ligands. Those ligands can either be 
upregulated upon stress or infection or be expressed physiologically by cells. 
Although several receptors are used by human and murine NK cells alike, even with 
identical ligands, other receptors are unique to individual species. This is a major 
reason why it is not possible to draw accurate conclusions from murine NK cell 
experiments for humans (and vice versa). The receptors can roughly be divided into 
three groups of receptor types with some exceptions based on their signaling 
properties [57].  
1.5.1 ITAM-signaling receptors 
The first group comprises receptors that signal through the interaction with signaling 
partner chains as the FcεRIγ chain, the CD3ζ chain or Dap12, which contain an 
immunoreceptor tyrosine-based activation motif (ITAM) to transduce a signal into the 
cell. Via a positively charged amino acid (a lysine or arginine) in the transmembrane 
region the receptor couples with a signal chain containing a negatively charged 
amino acid (commonly aspartate) in the transmembrane region [56]. These receptors 
include the natural cytotoxicity receptors (NCRs) NKp30, NKp44, NKp46 and the Fc 
receptor CD16. NKp46 and NKp30 are present on all human NK cells whereas 
NKp44 is only expressed on NK cells upon activation [112-114]. All of these 
receptors have been shown to bind viral ligands [115-117], but their cellular ligands 
remain less well understood. Only for the receptor NKp30 two cellular ligands have 
been postulated: the nuclear protein BAT3 and B7-H6 [118, 119]. Engagement of 
these receptors results in the phosphorylation of the ITAM of the signaling chain by 
an Src-family kinase. Phosphorylated ITAMs are then recognized and bound by the 
tyrosine kinases ‘spleen tyrosine kinase’ (SYK) or ’70 kDa zeta-chain associated 
protein’ (ZAP70), which then initiate a signaling cascade through adaptor proteins 
like ‘linker for activation of T cells’ (LAT), phosphatidyl-inositol-3-kinase (PI3K), 
phospholipase C γ (PLC) and Vav. This pathway is more or less identical for all 
ITAM-signaling receptors, including activating KIR receptors, e.g. as KIR2DS1, and 
activating members of the natural killer group 2 receptor family, as CD94/NKG2C 
[57]. 
1.5.2 SLAM-related receptors 
The second group of activating receptors contains the signaling lymphocyte 
activation molecule (SLAM) -related receptors (SRRs) [120]. These type I 
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transmembrane receptors belong to the Ig-superfamily and consist of usually two 
extracellular Ig-domains: an amino-terminal V-set domain and a C2-set domain [120]. 
The cytoplasmic part contains several so-called immunoreceptor tyrosine-based 
switch motifs (ITSMs), which are able to bind different adaptors and can mediate 
both activation and inhibition, though in human activation dominates [120]. On 
human NK cells, only three SRRs are expressed: 2B4 (CD244) [10], CD2-like 
receptor activating cytotoxic cells (CRACC) [121] and NK, T and B cell antigen 
(NTB-A) [122]. Whereas CRACC and NTB-A are homophilic [120], 2B4 binds the 
glycosylphosphatidylinositol (GPI)-linked CD48 which is expressed on various 
hematopoietic cells [123]. All three receptors can mediate cytotoxicity by NK cells, 
but due to its wide ligand expression 2B4 is the best-studied SRR on NK cells. Upon 
ligation, 2B4 is recruited into lipid rafts at the immune synapse in an actin-dependent 
way [124] and the ITSMs become phosphorylated by Src-family kinases [125]. This 
results in the association with the adaptors ‘SLAM-associated protein’ (SAP) [126] 
and ‘SH3 domain-binding protein 2’ (3BP2) [127]. SAP association causes the 
recruitment of the Src-family kinase Fyn that mediates a stronger phosphorylation of 
2B4 and adaptors. 3BP2 is phosphorylated after 2B4 ligation and recruits Vav-1, LAT 
and PLC-γ [57, 127]. This combinatorial signaling is crucial for NK cell activation and 
results in cytotoxicity and cytokine secretion by the NK cell. The presence of SAP 
and Fyn are essential for proper function of 2B4 as was shown in mice experiments 
[128]. In addition, defects in SAP result in fatal lymphoproliferative responses against 
EBV infection, often observed in patients with X-linked lymphoproliferative disease 
(XLP). In those patients the NK cell activation through 2B4 (and NTB-A) is impaired 
[129-133]. In addition to SAP, 2B4 and NTB-A also associate with the adaptor protein 
EAT-2 whereas CRACC only binds EAT-2 [120]. Situations in which these receptors 
mediate inhibitory instead of activating signals have been described [130] and a lack 
of stimulatory adaptor proteins like SAP was suggested to allow phosphatases to 
bind phosphorylated ITSMs [134]. Thus the decision whether SRRs act activating or 
inhibitory might be determined by the ratio of abundant receptor and adaptor [135]. 
1.5.3 NKG2D 
A third group is formed by the type II transmembrane C-type lectin-like receptor 
NKG2D that, in human, signals via the signaling partner ‘DNAX-activating protein of 
10 kDa’ or Dap10. In mouse, NKG2D can additionally associate with Dap12. Unlike 
other members of the NKG2 group that associate with CD94, NKG2D is expressed 
as a disulfide-linked homodimer associated with two disulfide-linked homodimers of 
Dap10 on NK cells and subsets of T cells [136, 137]. NKG2D relies on Dap10 for its 
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surface expression and signaling capacity, as the receptor itself only has a short 
cytoplasmic tail without signaling motifs [138]. As with other signaling chains, Dap10 
associates via a negatively charged aspartate in its transmembrane domain with a 
positively charged arginine in the transmembrane domain of NKG2D [138]. NKG2D 
recognizes a broad range of ligands such as the MHC class-I polypeptide-related 
chain A (MICA) and B (MICB), and the group of cytomegalovirus UL16 binding 
proteins (ULBPs) [139]. These ligands have been shown to be induced upon stress, 
infection and transformation [140] and thus grant NKG2D a major role as co-
activating receptor in immune responses in those circumstances [141]. Signaling of 
NKG2D is mediated by a special tyrosine-based signaling motif (YINM) in the 
cytoplasmic domain of Dap10. This motif can be activated by phosphorylation 
through Src-family kinases and is bound by both PI3K and Grb2 that mediate 
downstream signaling [142, 143]. NKG2D has also been shown to be recruited into 
lipid rafts at the IS upon ligation where the presence of Src-family kinases and other 
signaling adaptors assist signal transduction [144]. 
1.5.4 CD16 
An important NK cell receptor by its own right is CD16, the low affinity FcγRIIIA 
receptor, which plays a special role in NK cell activation [9]: CD16 recognizes bound 
IgG antibodies on the surface of cells and therefore enables NK cells to recognize 
effector proteins of the adaptive immune system on target cells, eventually resulting 
in killing of these target cells. In addition, CD16 is the only receptor on resting NK 
cells that results in full effector mechanisms upon ligation without co-activation by 
other receptors [47, 48]. CD16 associates with homo- or heterodimers of the FcεRIγ 
chain and/or the CD3ζ chain and signals similar to other ITAM-associated receptors 
[9]. 
1.5.5 Integrins 
Another essential group of co-activating NK cell receptors is formed by the integrins 
on NK cells. NK cells express several members of this family: The ß1 integrin VLA-4 
is expressed together with ß2 integrins like lymphocyte function-associated antigen 1 
(LFA-1). The main function of these receptors is to mediate adhesion with other cells 
by the ligation with their corresponding ligands, VCAM-1 (for VLA-4) and ICAM-1-5 
(for LFA-1), and to assist in the proper formation of an immunological synapse [43, 
45]. This is also achieved by their linkage through talin to the actin cytoskeleton 
[145]. Apart from this function, it has been shown that LFA-1 ligation is sufficient to 
induce the polarization of cytotoxic granules towards the immunological synapse and 
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therefore induces a crucial co-activating signal [47]. Integrins are able to signal 
‘inside-out’ as well as ‘outside-in’ and are regulated by a complex signaling system 
[57]. 
1.5.6 Other activating receptors 
Another activating receptor involved in adhesion is CD2: It is a member of the 
Ig-superfamily and binds CD58 as well as the 2B4 ligand CD48, although with a 
lower affinity [146]. It has been shown that CD2 enhances the adhesion of an NK cell 
with its target cells and is found together with LFA-1 in the pSMAC of an NK cell 
immune synapse [43, 45]. 
Further activating receptors on NK cells include the receptor DNAX accessory 
molecule 1 (DNAM-1). This receptor has been shown to be involved in the 
recognition of transformed cells as it recognizes the poliovirus receptor (CD155) and 
nectin-2 (CD112); both of these ligands may be upregulated on transformed cells 
[147, 148]. Other activating receptors include the less well-studied receptors CD160 
which binds to MHC class I ligands [149] and the C-type lectin-like receptors NKp80, 
which binds activation induced C-type lectin (AICL) found on monocytes and 
macrophages [38, 150], and NKp65 which binds keratinocyte-associated C-type 
lectin (KACL) [151]. 
 
1.6 Lipid rafts 
The main purpose originally described for the plasma membrane was the 
establishment of the cell as a separate unit from the surrounding environment [152]. 
Based on this function, the plasma membrane was regarded for a long time as a 
homogenous layer of lipids interspersed with proteins. This changed after the initial 
observations of phase separation in model membranes [153, 154].  
These observations in model systems led to the formulation of a cholesterol-
dependent lateral segregation of phases rich in cholesterol, sphingolipids and 
saturated lipids in the membrane. This segregation is based on different physical 
interactions between the lipids in the membrane: The rigid planar structure of 
cholesterol promotes interactions with adjacent straight and stiff hydrocarbon chains 
especially formed by saturated lipids; in contrast, the interaction with more kinked 
unsaturated hydrocarbon chains is disfavored [155]. The structure of cholesterol also 
drives adjacent hydrocarbon chains into their straight conformation, which results in a 
more ordered and thick membrane patch [156]. Lipids that cannot adopt a straight 
conformation, e.g. due to unsaturation, are displaced from the vicinity of cholesterol. 
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In addition, sphingolipids comprise several features that strengthen this association: 
Commonly, sphingolipids contain long saturated hydrocarbon chains. These favor 
association with cholesterol, but also enable the connection of the outer membrane 
leaflet with the inner leaflet via interdigitation [157]. In contrast to 
glycerophospholipids more commonly found outside these patches, sphingolipids 
also can accept as well as donate hydrogen bonds, which strengthen association 
with other sphingolipids and cholesterol as well [155].  
In model systems, the associative properties of these lipid species can be observed 
in the segregation into two phases: an ordered lipid phase (Lo) comprising 
cholesterol, sphingolipids and long saturated glycerophospholipids and a disordered 
lipid phase (Ld) comprising mostly unsaturated phospholipids [158].  
Based on these observations in model membranes, the possibility of membrane 
heterogeneity in living cells was discussed and their existence and composition was 
analyzed. Early studies on this topic made use of the resistance of such cholesterol-
rich membrane patches to detergent extraction in order to isolate them from cellular 
membranes. In these assays, the disordered phases are dissolved and separated 
from the detergent-resistant ordered phases by density centrifugation. The low 
density of the cholesterol-rich membrane patches coined the term ‘lipid rafts’, which 
float atop of the soluble fractions. Nowadays the more correct term ‘detergent-
resistant membranes’ (DRMs) is used for these isolated membrane fractions, which 
can be analyzed for their composition with various methods after isolation [159, 160].  
Though these studies give information about possible lipid raft association of 
membrane components, they have the disadvantage that artifacts can arise and they 
do not resemble the membrane of living cells [161]. At the time these studies were 
performed lipid rafts could not be visualized, which is due to their nanoscale size 
[162], and this lack of direct proof of the existence of lipid rafts caused a large-scale 
debate whether obtained data were based on artifacts or biased [161]. 
Up to now, a broad range of proteins has been shown to be located in lipid rafts or at 
least be associated with them [162]. However, the physical interactions between 
lipids seem insufficient to explain membrane heterogeneity in cells: the introduction 
of lipid raft-associated proteins in the already mentioned model membranes resulted 
in the localization of these proteins in the disordered phase rather than the ordered 
phase [163, 164]. Therefore, another factor has to be involved in membrane 
heterogeneity. This might well be the presence of proteins itself as well as the 
interaction of proteins with lipids. Indeed, studies have shown that the cellular 
membrane is full of membrane-associated proteins [165] and several modifications of 
proteins have been identified so far, which mediate or favor lipid raft localization: 
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GPI-anchors have been shown to mediate lipid raft association as shown by the 
constitutive DRM association of GPI-linked proteins [166]. Moreover, the modification 
of proteins with the saturated 16-carbon fatty acid palmitate has been shown to 
increase lipid raft affinity. This was found for example in certain Src-family kinases 
like Fyn which are enriched in lipid rafts [167]. However, palmitoylation alone does 
not seem to be sufficient for lipid raft recruitment as there are several palmitoylated 
proteins absent from lipid rafts.  
The association of proteins with certain types of lipids has also been shown [168]; 
dependent on the lipid this association can increase lipid raft affinity of the protein as 
well. Furthermore, the direct binding of cholesterol has been shown for certain 
proteins like caveolin-1 [169] and sphingolipids-binding sites have been described 
[170]; two additional types of interaction to increase the affinity for lipid rafts of 
proteins. The length of transmembrane proteins by itself has also been shown to 
influence localization of a membrane protein [171, 172]. Additionally, the interaction 
of non-raft membrane proteins with raft-associated membrane proteins might 
increase lipid raft association as well.  
 
In the last years, more and more data supporting the existence of lipid rafts emerged 
[162]; these also include the visualization of membrane patches on cellular 
membranes [163, 173]. Therefor, the heterogeneity of cellular membranes and the 
ability to form lipid rafts has been supported repeatedly. The current model of lipid 
rafts describes the presence of small nanosized dynamic assemblies of lipid raft 
components in a resting state in the membrane. These nanosized rafts can be 
activated to coalesce to larger rafts or even membrane macrodomains upon 
multimerization. This can be induced by ligand binding of associated receptors, or by 
the action of the underlying cytoskeleton, which has been shown to be crucial for lipid 
raft assembly [174]. These coalesced lipid rafts are supposed to be more 
heterogeneous in their composition and more suited for the corresponding function. 
A simplified illustration of resting state rafts and clustered rafts is presented in Figure 
3.  
 
So far, lipid rafts have been implicated in several cellular functions like membrane 
sorting throughout the Golgi, signaling and endocytosis as well as more specific 
functions in specialized cells [162, 175]. Whereas the sorting function predominantly 
relies on the segregation of the membrane domains and subsequent divergent 
destinations [175], the signaling function is based on the association of several 
signaling components as receptors or kinases with lipid rafts. So far, protein tyrosine 
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kinases, adaptor proteins, different G proteins as well as phosphoinositides have 
been associated with lipid rafts [159, 167, 176]. In the coalesced lipid rafts, all these 
signaling components come together and probably are protected from the action of 
excluded phosphatases, effectively forming a potent signaling platform [159]. 
 
1.6.1 Lipid rafts in NK cells 
Upon the formation of an activating NKIS, lipid rafts are clustered at the contact site 
of NK cell and target cell [49]. Initial signals are required to mediate this clustering, as 
the inhibition of proximal protein tyrosine kinases abolishes the lipid raft clustering 
[49]. In addition, the inhibition of the cytoskeleton was also shown to abolish the lipid 
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Figure 3: Simplified illustration of lipid raft organization [175]. (A) 
depicts small raft nanodomains in resting state. Non-raft proteins (1) 
reside in the disordered membrane, while diverse raft-associated 
proteins like GPI-anchored proteins (2), raft-associated transmembrane 
proteins (3) and palmitoylated proteins (4) are dynamically present in 
the nanodomains or the non-raft membrane. Residence in 
nanodomains might increase depending on a protein and its 
modifications. Upon ligation of nanodomain-resident receptors, the coalescence of small nanodomains 
can lead to larger domains finally resulting in a macrodomain or clustered lipid raft depicted in (B). This 
process is usually cytoskeleton-dependent but by means of simplicity it was omitted in the illustration. 
Raft-associated receptors are resident in the lipid rafts and are thus localized in a favoring environment 
to fulfill their function, e.g. signal transduction, while non-raft proteins as phosphatases are excluded. 
Dense membrane represents ordered cholesterol- and sphingolipids-rich membrane, whereas the 
unordered membrane represents membrane poor in cholesterol or sphingolipids, but rich in unsaturated 
glycerophospholipids. 
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raft clustering at the synapse indicating a possible involvement of the cytoskeleton in 
this process [177]. A similar dependency of lipid rafts on the cytoskeleton was 
observed in T cells [178]. 
Moreover, the clustering of lipid rafts is abolished if the NKIS is inhibitory instead of 
activating [177, 179]. It was shown that the lipid rafts were excluded in an active 
cytoskeleton-dependent mechanism from the inhibitory IS. Inhibitory receptors are 
excluded from lipid rafts but are able to signal independently from the cytoskeleton in 
order to displace the lipid raft-signaling platform from the NKIS. This was mediated 
through the activity of SHP-1, which is recruited to the IS by signaling inhibitory 
receptors [177, 179]. The involvement of lipid rafts during signal transduction in NK 
cells was also investigated in more detail for different NK cell receptors: For example, 
different activating NK cell receptors were associated with lipid rafts, either 
constitutively or upon ligation [124, 144, 180-182]: The activating NK cell receptor 
2B4 was shown to be localized into DRMs upon ligation and this was dependent on 
intact cytoskeleton and Src-family kinases. The phosphorylation of 2B4, which is 
required for 2B4-mediated signal transduction, is not sufficient to induce raft 
recruitment. Instead it is more likely that 2B4 is recruited into lipid rafts in an actin-
dependent way and phosphorylated there [124]. The receptor NKG2D was also 
shown to be localized into lipid rafts after receptor ligation or sensitive target cell 
contact [144]. These receptors are displaced from the lipid rafts in a resting state or 
by inhibition through inhibitory receptors, but accumulate in the lipid rafts in case of 
activation. Although the knowledge about the mechanism underlying the 
displacement of lipid rafts is increasing, the molecular mechanisms underlying the 
lipid raft recruitment of receptors upon stimulation are unknown.  
Different studies also showed that the ability of NK cells to lyse sensitive target cells 
was decreased if the lipid rafts were disturbed, e.g. by methyl-ß-cyclodextrin 
(MßCD)-mediated depletion of cholesterol [49, 124]. Thus lipid rafts play an essential 
role in the function of NK cells by merging the ligated activating receptors with 
essential signaling components at the aNKIS. 
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1.7 Aim of the thesis 
The research of the lipid raft theory is a growing field. It has been established that the 
cellular membrane is not just a homogenous barrier separating the cell from its 
surroundings. Instead, by applying heterogeneity in the membrane, a cell can 
orchestrate different functions. More and more components of these lipid rafts are 
identified; also several activating NK cell receptors have been shown to associate 
with this membrane microdomains upon ligation. However, the mechanisms 
underlying the recruitment of these receptors into the lipid rafts remain unknown. The 
present thesis therefore focused on the molecular mechanism involved in the 
recruitment of NK cell receptors: The SLAM-related receptor 2B4 and the C-type 
lectin-like receptor NKG2D were selected as representative NK cell surface receptors 
which are recruited into lipid rafts upon stimulation. These receptors were studied 
with detergent extraction methods for their lipid raft recruitment in order to identify 
crucial criteria for the recruitment mechanisms in the structure of the receptors.  
The second part of the thesis deals with the inhibitory NK cell receptor Siglec-7 that 
recognizes sialic acid ligands and dampens NK cell activity. A range of studies 
presented evidence for a potentially harmful exploitation of this receptor by tumors 
and different pathogens. In order to provide means to break this exploitation and 
obtain a new therapeutic and scientific tool, the aim was to develop a component 
capable to inhibit the Siglec-7 ligand interaction. We therefore developed and applied 
a functional Siglec-7 binding assay to screen a range of substances based on the 
structure of sialic acid and tested promising candidates in functional NK cell assays.   
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2 Materials and Methods 
2.1 Materials 
2.1.1 Vectors 
 
Name Use Source 
pCR2.1-TOPO Subcloning of PCR products Invitrogen, Carlsbad, CA 
pBABEplus Mammalian expression vector Addgene 
pMaxCloning Mammalian expression vector Addgene 
pMOW Mammalian expression vector Klingenmüller Lab 
pMOWplus Mammalian expression vector Replaced pMOW-MCS with 
MCS from pBABEplus  
pMXs-neo Mammalian expression vector Addgene 
 
2.1.2 Constructs 
 
Name Tag Size (bp) Vector Resistance Source 
2B4wt HA 1267 pBABEplus Puromycin Eissmann [134] 
2B4-CA HA 1267 pBABEplus Puromycin J. Endt  
2B4-D0 HA 1267 pBABEplus Puromycin Eissmann [134] 
2B4-YF HA 1267 pBABEplus Puromycin Eissmann [134] 
2B4-LAT-TM HA 1267 pBABEplus Puromycin Eissmann [134] 
2B4wt HA 1267 pMOWplus Puromycin This thesis 
2B4-CA HA 1267 pMOWplus Puromycin This thesis 
2B4-D0 HA 1267 pMOWplus Puromycin This thesis 
2B4-YF HA 1267 pMOWplus Puromycin This thesis 
2B4-LAT HA 1267 pMOWplus Puromycin This thesis 
2B4-FLVIIVIL-A HA 1267 pMOWplus Puromycin This thesis 
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2B4-SALFLGT-A HA 1267 pMOWplus Puromycin This thesis 
2B4-LACFCV-A HA 1267 pMOWplus Puromycin  This thesis 
2B4-FLV-A HA 1267 pMOWplus Puromycin This thesis 
2B4-IIV-A HA 1267 pMOWplus Puromycin This thesis 
2B4-ILS-A HA 1267 pMOWplus Puromycin This thesis 
DAP10wt FLAG  pMxs-neo G418 M. Sandusky 
Dap10-YF FLAG  pMxs-neo G418 M. Sandusky 
NKG2Dwt - 767 pBABEplus Puromycin M. Sandusky 
NKG2D∆cyt - 767 pBABEplus Puromycin M. Sandusky 
NKG2D-RA - 767 pBABEplus Puromycin M. Sandusky 
NKG2Dwt - 767 pMOWplus Puromycin This thesis 
NKG2D∆cyt - 767 pMOWplus Puromycin This thesis 
NKG2D-RA - 767 pMOWplus Puromycin This thesis 
 
2.1.3 Bacteria 
 
E. coli strain Use Source 
TOP10 Amplification of plasmids Invitrogen, Carlsbad, CA 
 
 
2.1.4 Cells 
 
If not indicated otherwise, cells were grown with 10 % (v/v) FBS and 1  % (v/v) 
Penicillin/Streptomycin in addition to the below given culture media constituents.  
 
Cell type Origin Culture medium 
BA/F3 Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol 
BA/F3 2B4wt Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
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BA/F3 2B4-CA Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-D0 Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-FLV-A Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-FLVIIVIL-A Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-IIV-A Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-ILS-A Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-LACFCV-A Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-LAT Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-SALFLGT-A Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3 2B4-YF Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 µg/ml Puromycin 
BA/F3  
NKG2Dwt DAP10wt 
Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 mM G418, 1 µg/ml Puromycin 
BA/F3 
NKG2Dwt Dap10-YF 
Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 mM G418, 1 µg/ml Puromycin 
BA/F3 
NKG2D∆cyt DAP10wt 
Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 mM G418, 1 µg/ml Puromycin 
BA/F3 
NKG2D∆cyt Dap10-YF 
Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 mM G418, 1 µg/ml Puromycin 
BA/F3 NKG2D-RA Murine pro B cell line RPMI, 0.5 mM 2-mercaptoethanol, 
1 mM G418 
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Human peripheral blood 
mononuclear cells 
(PBMC) 
Isolated from whole 
blood or buffy coats 
 
K562 Human 
erythroleukemic 
cell line 
IMDM 
Mel1106 Human melanoma 
cell line 
RPMI 
Primary human NK cells Isolated by negative 
selection from PBMCs 
IMDM, 10 % (v/v) human serum, 
1 % (v/v) NEAA, 1 % (v/v) sodium 
pyruvate, 100 IU/ml IL-2 
Phoenix ampho Adenovirus-
transformed 293T 
cell line 
DMEM 
 
2.1.5 Reagents 
 
Name Source 
5-Bromo-4-chloro-3-indoxyl-ß-
D-galactoside (X-Gal) 
Roth, Karlsruhe, Germany 
Agarose Gibco, Invitrogen, Carlsbad, CA 
Ampicillin Roth, Karlsruhe, Germany 
Bovine serum albumin (BSA) Serva, Heidelberg, Germany 
Cell culture media Gibco, Invitrogen, Carlsbad, CA 
Chromium-51 (51Cr) Hartmann Analytik, Braunschweig, Germany 
100 bp DNA ladder Invitrogen, Carlsbad, CA 
1 kb DNA ladder Invitrogen, Carlsbad, CA 
Fetal bovine serum (FBS) Gibco, Invitrogen, Carlsbad, CA 
Kanamycin Roth, Karlsruhe, Germany 
LB-Broth Invitrogen, Carlsbad, CA 
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Lipofectamine® 2000 Invitrogen, Carlsbad, CA 
Lymphocyte separation medium 
(LSM) 
PAA, Pasching, Germany 
MOPS buffer, 20x Invitrogen, Carlsbad, CA 
Non essential Amino acids 
(NEAA) 
Gibco, Invitrogen, Carlsbad, CA 
Nonfat dry milk powder Saliter, Obergünzburg, Germany 
NuPAGE® 10% Bis-Tris Gels Invitrogen, Carlsbad, CA 
Opti-MEM® Gibco, Invitrogen, Carlsbad, CA 
Penicillin/Streptomycin Gibco, Invitrogen, Carlsbad, CA 
Phytohemagglutinin (PHA-P) Sigma-Aldrich, St. Louis, MO 
Polybrene Sigma-Aldrich, St. Louis, MO 
Polyvinylidene fluoride (PVDF) 
membrane 
Millipore, Billerica, MA 
Precision Plus Protein Standard Bio-Rad, Hercules, CA 
Protein G agarose Invitrogen, Carlsbad, CA 
Protein G dynabeads Invitrogen, Carlsbad, CA 
Puromycin Sigma-Aldrich, St. Louis, MO 
Sodium Pyruvate Gibco, Invitrogen, Carlsbad, CA 
SuperSignal West Dura Thermo Fisher Scientific, Waltham, MA 
TAE buffer, 10x Invitrogen, Carlsbad, CA 
TrypLE™ Express Invitrogen, Carlsbad, CA 
X-ray films Pierce, Thermo Fisher Scientific, Waltham, MA 
 
2.1.6 Inhibitors 
 
All Siglec-7 inhibitors were produced in and obtained from the lab of Prof. Dr. 
Brossmer (Biochemistry Center, Heidelberg University, Heidelberg, Germany). 
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2.1.7 Buffers 
 
Name Components, Source 
DNA sample buffer 50 % (v/v) 
0.25 % (w/v) 
10 mM 
Glycerol 
Bromophenol blue 
EDTA 
FACS buffer 1x 
2 % (v/v) 
PBS 
FBS 
Igepal lysis buffer 10 % (v/v) 
10 % (v/v) 
1 mM 
1 mM 
TNE buffer, 10x 
Igepal stock solution 
PMSF 
Vanadate 
Igepal stock solution 10 % (v/v) Igepal CA-630 
MOPS buffer, 20x Invitrogen, Carlsbad, CA 
PBS, 10x  
(pH 7.4) 
1.37 M 
81 mM 
27 mM 
15 mM 
NaCl 
Na2HPO4 
KCl 
KH2PO4 
PBS, 1x Gibco, Invitrogen, Carlsbad, CA 
PBS-T 10 % (v/v) 
0.05 % (v/v) 
PBS, 10x 
Tween 20 
PBS-T/NaCl 10 % (v/v) 
0.05 % (v/v) 
0.5 M 
PBS, 10x 
Tween 20 
NaCl 
RBC wash buffer 1x 
0.1 % (w/v) 
2 mM 
PBS 
BSA 
EDTA 
Reducing sample buffer, 5x 
(pH 6.8) 
50 % (v/v) 
25 % (v/v) 
10 % (w/v) 
0.1 % (w/v) 
0.3125 mM 
Glycerol 
2-mercaptoethanol 
SDS 
Bromophenol blue 
Tris-HCl 
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Sucrose stock solution, 85 % 85 % (w/v) 
10 % (v/v) 
1 % (v/v) 
Sucrose 
TNE buffer, 10x 
Triton X-100 stock solution 
TAE buffer, 10x Invitrogen, Carlsbad, CA 
TNE buffer, 10x 
(pH 7.4) 
1.5 M 
50 mM 
200 mM 
NaCl 
EDTA 
Tris-HCl 
Triton X-100 lysis buffer 10 % (v/v) 
3 % (v/v) 
1 mM 
1 mM 
TNE buffer, 10x 
Triton X-100 stock solution 
PMSF 
Vanadate 
Triton X-100 stock solution 10 % (v/v) Triton X-100 
Western blot blocking buffer 1x 
5 % (w/v) 
PBS-T 
Nonfat dry milk powder 
Western blot transfer buffer 129 mM 
24 mM 
20 % (v/v) 
Glycine 
Tris 
Methanol 
 
2.1.8 Mouse monoclonal antibodies 
 
Name Conjugate Clone Source, Reference 
α-2B4 - C1.7 Immunotech, Beckman Coulter, 
Brea, CA 
 
α-2B4 PE C1.7 BioLegend, San Diego, CA  
α-CD45 - 69/CD45 Transduction Laboratories, BD, 
Franklin Lakes, NJ 
 
α-FLAG - M2 Sigma-Aldrich, St. Louis, MO  
α-Fyn - 25 Transduction Laboratories, BD, 
Franklin Lakes, NJ 
 
α-HA - 2C16 MBL, Biozol, Eching, Germany  
α-NKG2D - 149810 R&D Systems, Minneapolis, MN  
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α-NKG2D - 3.1.1.1 [144]  
α-NKG2D PE 1D11 BioLegend, San Diego, CA  
α-Siglec-7 - 194212 R&D Systems, Minneapolis, MN  
α-Siglec-7 PE F023-420 Pharmingen, BD, Franklin Lakes, 
NJ 
 
α-Siglec-9 - 191240 R&D Systems, Minneapolis, MN  
α-Siglec-9 PE 191240 R&D Systems, Minneapolis, MN  
IgG control - MOPC21 Sigma-Aldrich, St. Louis, MO  
IgG control PE MOPC21 BioLegend, San Diego, CA  
 
2.1.9 Secondary antibodies 
 
Name Conjugate Source 
Goat α-human IgG Biotin Jackson ImmunoResearch, 
West Grove, PA 
Goat α-mouse F(ab’)2 PE Jackson ImmunoResearch, 
West Grove, PA 
Goat α-mouse IgG HRPO Jackson ImmunoResearch, 
West Grove, PA 
 
2.1.10 Recombinant proteins 
 
Name Conjugate Source 
7-AAD - Pharmingen, BD, Franklin Lakes, NJ 
Annexin-V PE Pharmingen, BD, Franklin Lakes, NJ 
Human IL-15 - R&D Systems, Minneapolis, MN 
Human IL-2 - Hemagen Diagnostics, Columbia, MD 
Human Siglec-7-Fc 
fusion protein 
- R&D Systems, Minneapolis, MN 
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Human Siglec-9-Fc 
fusion protein 
- R&D Systems, Minneapolis, MN 
Streptavidin PE Jackson ImmunoResearch, West Grove, PA 
 
2.1.11 Enzymes  
 
All enzymes were used in buffers provided by the manufacturer. 
Name Use Source 
Calf intestinal alkaline 
phosphatase (CIAP) 
Dephosphorylation of DNA New England Biolabs, Ipswich, MA 
Neuraminidase 
(Arthrobacter 
ureafaciens 
α2-3,6,8,9-
Neuraminidase) 
Desialylation of cells Calbiochem, Merck, Darmstadt, 
Germany 
Restriction 
endonucleases 
Cutting of DNA New England Biolabs, Ipswich, MA 
T4 DNA ligase Ligation of DNA  New England Biolabs, Ipswich, MA 
Taq DNA polymerase PCR New England Biolabs, Ipswich, MA 
 
2.1.12 Oligonucleotides 
 
All oligonucleotides were synthesized by Thermo Fisher Scientific (Waltham, MA). 
Name Use Sequence (5’-3’) 
2B4-FLV-A fwd Cloning of 
2B4-FLV-A 
AAT TCA GAT TTT GGC CGG CAG CAG 
CAA TCA TCG TGA TTC TAA GCG CAC 
TGT TCC TTG GCA CCC TTG CCT GCT 
TCT GTG TGT GGA GGA GAA AGA GGC 
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2B4-FLV-A rev Cloning of 
2B4-FLV-A 
TCG AGC CTC TTT CTC CTC CAC ACA 
CAG AAG CAG GCA AGG GTG CCA AGG 
AAC AGT GCG CTT AGA ATC ACG ATG 
ATT GCT GCT GCC GGC CAA AAT CTG 
2B4-FLVIIVIL-A fwd Cloning of 
2B4-FLVIIVIL-A 
AAT TCA GAT TTT GGC CGG CAG CAG 
CAG CAG CAG CAG CAG CAA GCG CAC 
TGT TCC TTG GCA CCC TTG CCT GCT 
TCT GTG TGT GGA GGA GAA AGA GGC 
2B4-FLVIIVIL-A rev Cloning of 
2B4-FLVIIVIL-A 
TCG AGC CTC TTT CTC CTC CAC ACA 
CAG AAG CAG GCA AGG GTG CCA AGG 
AAC AGT GCG CTT GCT GCT GCT GCT 
GCT GCT GCT GCC GGC CAA AAT CTG 
2B4-IIV-A fwd Cloning of 
2B4-IIV-A 
AAT TCA GAT TTT GGC CGT TTT TGG 
TGG CAG CAG CAA TTC TAA GCG CAC 
TGT TCC TTG GCA CCC TTG CCT GCT 
TCT GTG TGT GGA GGA GAA AGA GGC 
2B4-IIV-A rev Cloning of 
2B4-IIV-A 
TCG AGC CTC TTT CTC CTC CAC ACA 
CAG AAG CAG GCA AGG GTG CCA AGG 
AAC AGT GCG CTT AGA ATT GCT GCT 
GCC ACC AAA AAC GGC CAA AAT CTG 
2B4-ILS-A fwd Cloning of 
2B4-ILS-A 
AAT TCA GAT TTT GGC CGT TTT TGG 
TGA TCA TCG TGG CAG CAG CAG CAC 
TGT TCC TTG GCA CCC TTG CCT GCT 
TCT GTG TGT GGA GGA GAA AGA GGC 
2B4-ILS-A rev Cloning of 
2B4-ILS-A 
TCG AGC CTC TTT CTC CTC CAC ACA 
CAG AAG CAG GCA AGG GTG CCA AGG 
AAC AGT GCT GCT GCT GCC ACG ATG 
ATC ACC AAA AAC GGC CAA AAT CTG 
2B4-LACFCV-A fwd Cloning of 
2B4-LACFCV-A 
AAT TCA GAT TTT GGC CGT TTT TGG 
TGA TCA TCG TGA TTC TAA GCG CAC 
TGT TCC TTG GCA CCG CAG CAG CAG 
CAG CAG CAT GGA GGA GAA AGA GGC 
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2B4-LACFCV-A rev Cloning of 
2B4-LACFCV-A 
TCG AGC CTC TTT CTC CTC CAT GCT 
GCT GCT GCT GCT GCG GTG CCA AGG 
AAC AGT GCG CTT AGA ATC ACG ATG 
ATC ACC AAA AAC GGC CAA AAT CTG 
2B4-SALFLGT-A fwd Cloning of 
2B4-SALFLGT-A 
AAT TCA GAT TTT GGC CGT TTT TGG 
TGA TCA TCG TGA TTC TAG CAG CAG 
CAG CAG CAG CAG CAC TTG CCT GCT 
TCT GTG TGT GGA GGA GAA AGA GGC 
2B4-SALFLGT-A rev Cloning of 
2B4-SALFLGT-A 
TCG AGC CTC TTT CTC CTC CAC ACA 
CAG AAG CAG GCA AGT GCT GCT GCT 
GCT GCT GCT GCT AGA ATC ACG ATG 
ATC ACC AAA AAC GGC CAA AAT CTG 
2B4 Seq fwd Sequencing CTC ATC AAG GCA GCT CAG C 
2B4 Seq rev Sequencing CAA TCG AGC AGG GTT CTG G 
pMOW Seq fwd Sequencing GAT CCT CCC TTT ATC CAG C 
pMOW Seq rev Sequencing GCA ACA TAG TTA AGA ATA CC 
 
2.1.13 Kits 
 
Name Use Source 
First strand cDNA 
synthesis kit 
RT-PCR Roche Diagnostics, Basel, 
Switzerland 
Gel extraction kit DNA fragment purification Qiagen, Hilden, Germany 
NK cell negative 
isolation kit 
Isolation of human NK cells Invitrogen, Carlsbad, CA 
Plasmid Midi kit Plasmid DNA purification Qiagen, Hilden, Germany 
Plasmid Mini kit Plasmid DNA purification Qiagen, Hilden, Germany 
RNeasy Mini kit RNA isolation Qiagen, Hilden, Germany 
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2.2 Methods 
2.2.1 Molecular biology 
 
Isolation of RNA 
RNA was isolated from BA/F3 cells using the RNeasy Mini kit according to the 
instructions of the manufacturer. 
 
Reverse Transcription of RNA 
The First strand cDNA synthesis kit was applied according to the manufacturers 
instructions in order to generate cDNA from RNA. 
 
Polymerase chain reaction (PCR) 
DNA sequences were amplified from cDNA via PCR. For each respective task, 
different conditions and primers were applied. 
 
Ligation of DNA fragments 
Insert and vector DNA were mixed at an approximate ratio of 5:1 in the 
corresponding ligation buffer. Prior to incubation for 1 h at room temperature or 16 h 
at 16°C, 2 units of T4 DNA ligase were added to the mixture. The ligation product 
was then used for transformation of competent TOP10 bacteria. 
 
Transformation of bacteria 
Competent TOP10 bacteria were used for transformation according to the 
manufacturers instructions. Transformed bacteria were grown on LB agar plates at 
37°C for 24h with the appropriate selection medium. 
 
Plasmid DNA isolation 
TOP10 bacteria were grown in 1x LB medium overnight at 37°C stirring. Appropriate 
selective media were added to the medium prior. After overnight growth, bacteria 
were harvested by centrifugation at 3’500 x g for 5 min. Subsequently, plasmid DNA 
was isolated using the plasmid Mini or Midi kit according to the manufacturers 
instructions. 
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DNA restriction digest 
For DNA digests, between 1 and 2 µg of DNA were incubated with 2 units of the 
respective DNA restriction endonucleases for at least 1 h at 37°C. The reactions 
were performed in the reaction buffers recommended by the manufacturer. 
 
Agarose gel electrophoresis 
DNA fragments were separated using 1 – 2 % (w/v) agarose gels prepared in TAE 
buffer and 0.0001 % (v/v) ethidium bromide. Prior to loading on a gel, the DNA was 
mixed with DNA loading buffer. For size reference of the DNA fragments, 100 bp 
and/or 1 kb DNA ladders were run in the gels. 
 
Isolation of DNA fragments from agarose gels 
DNA fragments were excised from the gel and processed using the gel extraction kit 
according to the manufacturers instructions. 
 
2.2.2 Cell biology 
 
Cell Culture 
All cells were grown at 37°C and 5 % CO2 in a humidified incubator under sterile 
conditions. Cell lines were split regularly either by medium exchange (suspension 
cells) or trypsinization (adherent cells) every 2 – 3 days and cell culture flasks were 
replaced regularly. Cryostocks of cells were prepared by freezing the cells in 10 % 
(v/v) DMSO in FBS at 75°C. For long-term storage, cryostocks were put to liquid 
nitrogen. Cell lines were thawed regularly or prior to a batch of experiments. FBS and 
human serum were heat inactivated by incubation for 30 min at 56°C prior to use. 
 
Red blood cell (RBC) isolation 
RBCs were obtained from whole blood or buffy coats: 2 – 3 ml blood were washed 
with 10 ml PBS and centrifuged at 3’000 x g for 10 min at room temperature. 2 ml of 
the pelleted RBCs were harvested and then washed twice with 13 ml of RBC wash 
buffer and centrifuged at 2’000 x g for 10 min at room temperature. With the final 
pellet of RBCs a 0.1 % (v/v) RBC solution in RBC wash buffer was prepared and 
stored at 4°C for further experiments. 
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NK cell isolation 
Human polyclonal NK cells were isolated from whole blood or buffy coats. First, 
PBMCs were separated from the remaining cells by a density gradient centrifugation 
of the blood over lymphocyte separation medium (LSM). The PBMCs were harvested 
from the gradients and washed. NK cells were isolated from the PBMCs by the use 
of a NK cell negative isolation kit. NK cell yield (NKp46+, CD3-, CD56+ cells) ranged 
from 90 – 99 % of the purified cells. Purified cells were maintained in primary NK cell 
medium at a concentration of 2 x 106 cells/ml. 
 
NK cell stimulation 
NK cell were stimulated with 100 IU/ml hIL-2 24 h prior to use in experiments. 
 
Transduction and transfection of BA/F3 
2 x 106 Phoenix ampho cells were seeded in a 25 cm2 culture flask in the 
corresponding medium and incubated overnight at 37°C and 5 % CO2. Phoenix cells 
were then transfected with 10 µg of pMOWplus or pMXs-neo vector using 
Lipofectamine® 2000 and Opti-MEM® according to the manufacturers instructions. 
Phoenix cells were incubated for another 24 h at 37°C with 5 % CO2. The next day, 
the medium was replaced with BA/F3 medium and Phoenix cells were incubated for 
another 24 h. The supernatant then was harvested and used for the transduction of 
BA/F3 cells. 5 x 105 BA/F3 cells were resuspended in 2 ml supernatant containing 
retroviral particles together with 5 µg/ml polybrene. Cells were then centrifuged with 
1’350 x g for 90 min at room temperature in order to bring cells and viral particles 
together. After centrifugation, the cells were incubated at 37°C with 5 % CO2 
overnight. The next day, the medium was replaced with fresh BA/F3 medium. 24 h 
after medium exchange, the vector-specific selection medium was added to the 
culture and further on used in culture of the transduced cells. 
 
BA/F3 stimulation  
In order to stimulate the receptors on BA/F3 cells for lipid raft assays, the receptors 
were cross-linked with antibodies: 1 x 108 cells were resuspended in 1 ml cold PBS 
and incubated for 10 min on ice with 10 µg/ml of primary murine antibody. Cells were 
then washed with 500 µl cold PBS, pelleted by centrifugation at 480 x g for 5 min at 
4°C and resuspended in 1 ml cold PBS with 10 µg/ml goat-α-mouse secondary 
antibody. Negative controls were incubated for 10 min on ice, whereas positive 
controls and samples were stimulated for 10 min at 37°C. Cells were then washed 
with 500 µl cold PBS and pelleted by centrifugation as done before.  
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BA/F3 cell lysis 
For lipid raft assays, 1 x 108 stimulated BA/F3 were resuspended in 1 ml 0.3 % Triton 
X-100 lysis buffer and incubated for 30 min on ice. Lysates were then homogenized 
with 10 strokes of a glass dounce homogenizer (loose-fit). 
 
Flow cytometry 
Surface staining of cells was performed in 96-well V-bottom plates. 1 x 105 cells were 
resuspended in 50 µl fluorescence-activated cell sorting (FACS) buffer with 10 µg/ml 
of the corresponding unlabeled primary antibody or a concentration recommended by 
the manufacturer in case of labeled primary antibodies. In case of unlabeled primary 
antibodies, the cells were incubated for 20 min on ice, then washed with 150 µl 
FACS buffer and pelleted by centrifugation at 480 x g for 5 min at 4°C. These cells 
were then resuspended in 50 µl FACS buffer with 0.5 % fluorophore-labeled 
secondary antibody. Cells in presence of fluorophore-labeled antibodies (both 
primary and secondary) were incubated again for 20 min at 4°C but in exclusion of 
light in order to protect the light-sensitive fluorophores. Cells were then washed again 
with 50 µl FACS buffer, pelleted by centrifugation at 480 x g for 5 min at 4°C and 
then resuspended in 150 µl FACS buffer containing 2 % formaldehyde for fixation. 
Cells were then analyzed using a BD FACScalibur device and results were evaluated 
and presented with the FlowJo software from Treestar. All histograms were 
presented as % of Max. 
 
FACS-based Siglec inhibition assay 
To assess the inhibitory potential of the Siglec inhibitors, Siglec fusion proteins were 
incubated with the inhibitors and subsequently tested for their ability to bind sialic 
acids on RBCs: 50 µl of a 0.2 µg/ml Siglec-Fc fusion protein solution in PBS was 
incubated with various concentrations of the corresponding siglec inhibitors for 10 
min at room temperature to allow inhibitor binding. Meanwhile, 50 µl of the previously 
prepared 0.1 % RBC solution were pelleted by centrifugation at 2’000 x g for 5 min at 
4°C. After the incubation, the RBCs were resuspended in the inhibitor/Siglec-Fc 
mixture and incubated for 20 min on ice to allow residual binding of the Siglec-Fc 
fusion protein to the sialic acids on the RBCs. RBCs were then washed with 150 µl 
FACS buffer and centrifuged at 2’000 x g for 5 min at 4°C. For detection of Siglec 
binding, the RBCs were resuspended in 50 µl FACS buffer with 10 µg/ml biotin-
conjugated goat-α-human antibody and incubated for 20 min on ice. The RBCs were 
then washed and pelleted as before, resuspended in 50 µl FACS buffer with 1:200 
Streptavidin-PE and incubated for 20 min on ice in exclusion of light due to the 
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fluorophore. Finally, the RBCs were again washed and pelleted, then resuspended in 
150 µl FACS buffer with 2 % formaldehyde and analyzed on a BD FACScalibur 
device. Data were evaluated using the FlowJo software. Percent inhibition of Siglec 
binding by inhibitors was calculated from the mean fluorescence intensity (MFI) 
values with the following equation: 
 %  𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛   =   100 − 𝑀𝐹𝐼  𝑠𝑡𝑎𝑖𝑛𝑒𝑑  𝑅𝐵𝐶𝑠  𝑤𝑖𝑡ℎ  𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟 −𝑀𝐹𝐼  𝑢𝑛𝑠𝑡𝑎𝑖𝑛𝑒𝑑  𝑅𝐵𝐶𝑠𝑀𝐹𝐼  𝑠𝑡𝑎𝑖𝑛𝑒𝑑  𝑅𝐵𝐶𝑠   𝑥  100   
 
Structures of inhibitors were illustrated with the ISIS/Draw software from MDL 
Information systems. 
 
FACS-based viability assay 
IL-2 activated human NK cells were assessed for their viability after Siglec inhibitor 
treatment: 1 x 105 human IL-2 activated NK cells were incubated for 24 h at 37°C and 
5 % CO2 with NK cell medium in the presence of Siglec inhibitors at various 
concentrations. The NK cells were then washed with fresh medium and pelleted by 
centrifugation at 480 x g for 5 min at 4°C. Subsequently, the NK cells were stained 
with 7-AAD and Annexin-V-PE according to the manufacturers instructions in 
Annexin-V-binding buffer. NK cells were then analyzed for their viability using a BD 
FACScalibur device and the FlowJo software. 
 
Chromium release assay 
Mel1106 or K562 were used as target cells in chromium release assays. The target 
cells were grown to mid-log phase, then 5 x 105 cells were harvested, resuspended 
in assay medium (IMDM medium containing 10 % FBS and 1 % 
Penicillin/Streptomycin) and labeled for 1 h at 37°C with 100 µCi 51Cr (3 MBq). Target 
cell were then washed twice and resuspended in fresh medium with a concentration 
of 5 x 104 target cells/ml. IL-2-activated human NK cells were used as effector cells in 
all chromium release assays. Antibody and Siglec inhibitor dilutions were prepared in 
96-well U-bottom plates and effector cells were added 15 min prior to target cells in 
dependence of the final effector to target ratio to the 96-well plate. All combinations 
were tested in triplicates. 5 x 103 target cells were then added to all wells and the 
plates were incubated for 4 h at 37°C with 5 % CO2. For maximum 51Cr release, 
labeled target cells were incubated with 1 % Triton X-100 and for spontaneous 51Cr 
release labeled target cells were incubated with medium alone. After the 4 h 
incubation, supernatants were harvested and chromium release was measured in a 
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γ-counter. The percentage of specific release in the assay was calculated with the 
following equation: 
 %  𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐  𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =    (𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙  𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠  𝑟𝑒𝑙𝑒𝑎𝑠𝑒)(𝑚𝑎𝑥𝑖𝑚𝑢𝑚  𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠  𝑟𝑒𝑙𝑒𝑎𝑠𝑒)   𝑥  100 
 
2.2.3 Protein biochemistry 
 
Lipid raft assay 
BA/F3 lysates were mixed 1:1 with cold 85 % sucrose solution, resulting in a 42.5 % 
sucrose/lysate mixture. With the lysate/sucrose mixture and sucrose solutions of 
various concentrations, a discontinuous gradient was prepared in an ultracentrifuge 
tube. The lysate mix was used to overlay 500 µl 85 % sucrose solution. The lysate 
mix was then overlaid with 6 ml 35 % sucrose lysis buffer and this phase was 
overlaid with 3.5 ml 5 % sucrose lysis buffer. This gradient was then centrifuged in an 
ultracentrifuge at 200’000 x g for 16 – 20 h at 4°C. After centrifugation, the gradients 
were harvested and fractionated into 2 ml fractions resulting in 6 fractions from top to 
bottom: 1 (discarded), 2/3, 4/5, 6/7, 8/9 and 10/11. Detergent-resistant membrane 
(DRM) fractions were directly processed for immunoprecipitation or SDS-PAGE and 
then stored at -20°C. 
 
Immunoprecipitation 
For the analysis of 2B4 raft recruitment, an immunoprecipitation step was included in 
order to remove unspecific signals from the lipid raft fractions. To this end, 500 µl of 
each fraction were mixed with 500 µl Igepal lysis buffer with either 20 µl Protein G 
agarose or 10 µl Protein G dynabeads together with 1 µg primary antibody. The 
mixture was then incubated with gentle agitation for 1 h at 4°C. Subsequently, beads 
were either washed by centrifugation (agarose) or with magnets (dynabeads) for at 
least 3 times with Igepal lysis buffer. Beads were then further on processed for 
western blot analysis. 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Lipid raft assays fraction samples (untreated or immunoprecipitated) were mixed with 
reducing sample buffer and boiled at 95°C for 10 min. Samples were then 
centrifuged for 1 min at 20’000 x g and loaded on NuPAGE® 10% Bis-Tris gels. In 
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addition, Precision Plus Protein Standard was loaded as a size reference. For 
separation, the gels were run for 75 min at 150 V in MOPS buffer. 
 
Western blot 
Following SDS-PAGE, the proteins were transferred unto polyvinylidene difluoride 
(PVDF) membranes: PVDF membranes were activated with methanol and then 
placed on the gels. Subsequently, protein transfer was performed for 100 min at 200 
mA in western blot transfer buffer. After western blotting, the membranes were 
blocked for 1 h with gentle agitation in western blot blocking buffer and subsequently 
washed at least 3 times with PBS-T. Membranes were then incubated overnight at 
4°C and with gentle agitation with primary antibody. Membranes were washed at 
least 3 times with PBS-T/NaCl and then incubated for 1 h with horseradish-
peroxidase (HRPO)-conjugated goat-α-mouse secondary antibody at a dilution of 
1:5’000-20’000 in western blot blocking buffer with gentle agitation at room 
temperature. Membranes were again washed at least 3 times with PBS-T and 
developed using SuperSignal West Dura and X-ray films. Films were scanned using 
a GS-800 densitometer from Bio-Rad.  
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3 Results 
3.1 Mechanisms of lipid raft recruitment of NK cell receptors 
3.1.1 Lipid raft recruitment of 2B4 (CD244) 
It has been previously shown, that the human NK cell surface receptor 2B4 (h2B4) is 
recruited into lipid rafts by a cytoskeleton-dependent mechanism upon receptor 
cross-linking [124]. The exact nature of this mechanism so far remains unknown. In 
order to elucidate this mechanism, we generated h2B4 mutants to inactivate certain 
domains and motifs in 2B4 that might be responsible for the raft recruitment of this 
receptor. The role of the transmembrane domain was to be analyzed by the 
exchange of the 2B4 transmembrane domain with the LAT transmembrane domain, 
as this protein has been reported to be constitutively present in lipid rafts (mutant 
2B4-LAT) [183]. This mutant should allow for constitutive lipid raft recruitment of 2B4. 
In another attempt to achieve impaired raft recruitment, we inactivated all four ITSMs 
of 2B4 by mutating the phosphotyrosines to phenylalanines (mutant 2B4-YF) in order 
to block adaptor binding and analyze the influence of these adaptors on the raft 
recruitment of 2B4. We also deleted the cytoplasmic domain of 2B4 by insertion of a 
stop codon in order to abolish any influence by this domain (mutant 2B4-D0). These 
mutants are depicted in Figure 4. 
 
Figure 4: Schematic representation of h2B4 mutations. Constructs include 2B4wt (wildtype), 2B4-LAT 
(2B4 transmembrane domain replaced with LAT transmembrane domain), 2B4-YF (phosphotyrosines 
mutated into alanines) and 2B4-D0 (deleted cytoplasmic domain). 
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These 2B4 mutants were transduced into BA/F3 cells and these BA/F3 cells were 
sorted for their 2B4 expression levels by flow cytometry, which resulted in BA/F3 
cells with a stable expression of all 2B4 mutants on the cell surface (Figure 5A). 
BA/F3 cells were used to analyze the lipid raft recruitment of NK cell receptors, 
because this cell line shares the lymphoid lineage of NK cells but is devoid of other 
NK cell-related receptors that might influence the lipid raft behavior additionally.  
The cells were stimulated by antibody cross-linking of 2B4, then lysed and separated 
for raft (DRM) and non-raft fractions with a lipid raft density sucrose gradient. The 
fractions were subsequently immunoprecipitated for 2B4 or directly applied to 
western blot analysis. All constructs were first tested in this way whether a stimulus 
resulted in increased DRM recruitment in comparison to an unstimulated sample of 
the same construct (data not shown). Unstimulated and stimulated wildtype 2B4 
were used as a reference and control for proper DRM recruitment in each assay. 
Figure 5 shows representative results for wildtype 2B4 DRM recruitment. In all lipid 
raft assays, the protein tyrosine phosphatase CD45 serves as a non-raft marker and 
the palmitoylated Src-family kinase Fyn as a ‘lipid raft’ marker in order to enable the 
distinction between those two phases. As shown in Figure 5, wildtype 2B4 is only 
recruited towards the DRM fraction upon stimulation of the receptor. Due to the 
variability of these assays and the saturation level of the blots, we neglected 
quantification and relied on qualitative differences for all experiments. 
 
A 
 
 
 
B 
 
C 
 
Figure 5: Surface expression of 2B4 constructs on BA/F3 cells and representative Western blots of 
sucrose density gradient fractions (n=4). (A) BA/F3 cells were stained with a 2B4-specific antibody (bold 
lines) or with an isotype matched control (shaded). All histograms are presented as % of Max. (B-C) 
Wildtype unstimulated (B) and stimulated (C) 2B4 constructs were tested for DRM recruitment. Samples 
were either stimulated by 2B4 crosslinking for 10 min at 37°C (x-link) or left unstimulated with a control 
antibody at 4°C (no x-link). Cells were then lysed and applied to the sucrose density gradient. Gradients 
were fractionated, either applied to 2B4-IP first or directly applied to Western blotting. Membranes were 
analyzed for 2B4 (38 kDa + glycosylation), Fyn (59 kDa) as lipid raft marker and CD45 (147 kDa) as non-
raft marker with specific antibodies. 
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All mutants were then tested with such lipid raft assays; representative results are 
shown in Figure 6. For practical reasons, control samples are only presented for 
wildtype 2B4; all 2B4 mutants are completely excluded from DRM fractions if 
unstimulated (data not shown). 
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Figure 6: Representative Western blots of sucrose density gradient fractions (n=4). Unstimulated h2B4 
wildtype (A) and stimulated wildtype (B), 2B4-LAT (C), 2B4-YF (D) and 2B4-D0 (E) constructs were 
tested. Samples were either stimulated by 2B4 crosslinking for 10 min at 37°C (x-link) or left 
unstimulated with a control antibody at 4°C (no x-link). Cells were then lysed and applied to the sucrose 
density gradient. Gradients were fractionated, either applied to 2B4-IP first or directly applied to Western 
blotting. Membranes were analyzed for 2B4, Fyn as lipid raft marker and CD45 as non-raft marker with 
specific antibodies. 
 
Unexpectedly, the mutation replacing the transmembrane domain of 2B4 with the 
transmembrane domain of LAT (2B4-LAT) did not result in the constitutive 
recruitment of the receptor into the DRM fraction (Figure 6C). In contrast, the 2B4-
LAT receptor was completely excluded from the DRM fraction even under stimulating 
conditions. Interestingly, the mutation of the ITSMs of 2B4 (2B4-YF) did not cause a 
major impairment in DRM recruitment (Figure 6D). This was supported by the results 
of the cytoplasmic deletion mutant (2B4-D0), which did not show any change in DRM 
recruitment compared to the wildtype controls (Figure 6E).  
Besides the replacement of the transmembrane domain of h2B4 with the 
transmembrane domain of LAT, we replaced the transmembrane domain with a 
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longer fraction of LAT as well as a mutated transmembrane domain of FcγRIIA 
described to mediate constitutive lipid raft association [184]. Both of these mutants 
were constitutively excluded from the DRM fractions (data not shown). Thus, 
although the exact reason for the 2B4-LAT mutant exclusion from DRM fractions was 
unknown, it was clear that the transmembrane domain of 2B4 has an important 
influence on the recruitment into lipid rafts.  
To this end, we generated new mutants of h2B4: The transmembrane domain of 2B4 
consists of 21 amino acids: FLVIIVILSALFLGTLACFCV (in single letter code). In 
order to identify the crucial parts within the transmembrane domain, we divided the 
domain into three parts and produced a substitution mutant with alanines for each 
part, resulting in the mutants 2B4-FLVIIVIL-A, 2B4-SALFLGT-A and 2B4-LACFCV-A 
(Figure 7). 
 
 
Figure 7: Schematic representation of h2B4 mutations. Constructs include 2B4wt (wildtype), 2B4-
FLVIIVIL-A (FLVIIVIL of transmembrane domain mutated to alanines), 2B4- SALFLGT-A (SALFLGT of 
transmembrane domain mutated to alanines) and 2B4-LACFCV-A (LACFCV of transmembrane domain 
mutated to alanines). 
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Again those mutants were transfected into BA/F3 cells and stable clones were sorted 
by flow cytometry. As can be seen in Figure 8A, the surface expression of these 
constructs on BA/F3 cells was uniform.  
 
These 2B4 mutants were then tested for lipid raft recruitment with similar sucrose 
density gradients as done with the previous mutants (Figure 8). 
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Figure 8: Surface expression of 2B4 constructs on BA/F3 cells and representative Western blots of 
sucrose density gradient fractions (n=5). (A) BA/F3 cells were stained with a 2B4-specific antibody (bold 
lines) or with an isotype matched control (shaded). All histograms are presented as % of Max. (B-F) 
Unstimulated h2B4 wildtype (wt) (B) and stimulated wildtype (C), FLVIIVIL-A- (D), SALFLGT-A- (E) and 
LACFCV-A- (F) 2B4 constructs were tested. Samples were either stimulated by 2B4 crosslinking for 10 
min at 37°C (x-link) or left unstimulated with a control antibody at 4°C (no x-link). Cells were then lysed 
and applied to the sucrose density gradient. Gradients were fractionated, either applied to 2B4-IP or 
directly applied to Western blotting. Membranes were analyzed for 2B4, Fyn as lipid raft marker and 
CD45 as non-raft marker with specific antibodies. 
 
The mutation of the three parts of the 2B4 transmembrane domain had different 
effects: While the mutation of the FLVIIVIL caused a moderate impairment in DRM 
recruitment upon stimulation (Figure 8D), the mutation of SALFLGT did not cause a 
major impairment (Figure 8E). In contrast to the SALFLGT substitution, the LACFCV 
substitution caused a severe impairment of DRM recruitment (Figure 8F). Overall, 
the effects were decreasing in strength with the LACFCV the most crucial domain, 
then followed by FLVIIVIL and finally SALFLGT with a minor role. These results 
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hinted toward the importance of the LACFCV part of the transmembrane domain for 
the raft recruitment of 2B4. In fact, the two cysteines in this domain create a ‘CxC’ 
motif that has been previously reported to influence the behavior of murine 2B4 and 
the lytic function of murine NK cells [185]. Additionally, this CxC motif is recognized 
as a positive hit by the palmitoylation prediction software CSS-Palm 3.0 [186].  
 
In order to check for the importance of this CxC motif, we generated a mutant 
substituting both cysteines in this motif with alanines as shown in Figure 9 (2B4-CA).  
 
 
Figure 9: Schematic 
representation of h2B4 
mutations. Constructs are 
2B4wt (wildtype) and 
2B4-CA (CxC motif in 
transmembrane domain 
substituted with AxA). 
 
 
The surface expression of this mutant was similar to that of the other 2B4 constructs 
as shown in Figure 8A. In accordance with the assumed importance of the CxC 
motif, the DRM recruitment of the 2B4-CA mutant upon stimulation was drastically 
abolished (Figure 10).  
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Figure 10: Representative Western blots of sucrose density gradient fractions (n=5). Unstimulated h2B4 
wildtype (wt) (A) and stimulated (B), 2B4-CA (C) and 2B4-LACFCV-A (D) constructs were tested. 
Samples were either stimulated by 2B4 crosslinking for 10 min at 37°C (x-link) or left unstimulated with a 
control antibody at 4°C (no x-link). Cells were then lysed and applied to the sucrose density gradient. 
Gradients were fractionated, either applied to 2B4-IP or directly applied to Western blotting. Membranes 
were analyzed for 2B4, Fyn as lipid raft marker and CD45 as non-raft marker with specific antibodies. 
 
From these data it can be concluded that the CxC motif located in the LACFCV 
sequence in the transmembrane domain of 2B4 is essential for the lipid raft 
recruitment of 2B4. 
 
In order to elucidate whether palmitoylation is the underlying mechanism of 2B4 raft 
recruitment, we applied the palmitoylation inhibitor 2-bromopalmitate to block 
palmitoylation of wildtype 2B4 in BA/F3 cells. However, the inhibitor did not show any 
effect on 2B4 nor on our palmitoylation control Fyn (data not shown) and thus did not 
result in reliable data. 
 
Apart from the effect the LACFCV part and the CxC motif mediate on the raft 
recruitment, we observed an effect of the FLVIIVIL part as well. Therefore, we 
constructed three partial mutants of this sequence as well, resulting in the mutants 
2B4-FLV-A, 2B4-IIV-A and 2B4-ILS-A, which are depicted in Figure 11.  
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Figure 11: Schematic representation of h2B4 mutations. Constructs include 2B4wt (wildtype), 2B4-FLV-
A (FLV of transmembrane domain substituted with alanines), 2B4-IIV-A (IIV of transmembrane domain 
substituted with alanines) and 2B4-ILS-A (ILS of transmembrane domain substituted with alanines). 
 
These mutants were transduced into BA/F3 cells as described for the previous 
mutants and BA/F3 2B4 cells were selected for the stable expression of the 2B4 
constructs. The 2B4 constructs were expressed to a similar extent by all BA/F3 cells 
(Figure 12A). 
 
Again, the mutated receptors were assayed for their DRM recruitment with sucrose 
density gradients, shown in Figure 12. 
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Figure 12: Surface expression of 2B4 constructs on BA/F3 and representative Western blots of sucrose 
density gradient fractions (n=5). (A) BA/F3 cells were stained with a 2B4-specific antibody (bold lines) or 
with an isotype matched control (shaded). All histograms are presented as % of Max. (B-F) 
Unstimulated h2B4 wildtype (B) and stimulated wildtype (C), FLV-A- (D), IIV-A- (E) and ILS-A- (F) 2B4 
constructs were tested. Samples were either stimulated by 2B4 crosslinking for 10 min at 37°C (x-link) 
or left unstimulated with a control antibody at 4°C (no x-link). Cells were then lysed and applied to the 
sucrose density gradient. Gradients were fractionated, either applied to 2B4-IP first or directly applied to 
Western blotting. Membranes were analyzed for 2B4, Fyn as lipid raft marker and CD45 as non-raft 
marker with specific antibodies. 
 
As with the previous mutants of the 2B4 transmembrane domain, the substitutions of 
different parts of the FLVIIVIL sequence led to differential effects on the DRM 
recruitment of 2B4: The substitution of IIV caused a moderate impairment in DRM 
recruitment in all experiments (Figure 12E). In contrast, the effect of both the FLV 
and ILS substitution caused variant, yet more severe impairments of the 2B4 DRM 
recruitment than the IIV substitution (Figure 12D, F). 
 
3.1.2 Lipid raft recruitment of NKG2D 
We also investigated the structural basis for lipid raft recruitment of the NK cell 
surface receptor NKG2D. Unlike 2B4, NKG2D surface expression is strongly 
dependent on the presence of an adaptor protein. On human NK cells this adaptor 
protein is exclusively Dap10 [138] whereas Dap12 is bound by murine NKG2D as 
well. In a previous study, Endt et al. [144] showed that wildtype human NKG2D was 
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recruited to lipid rafts upon receptor stimulation. In order to check for the dependency 
of human NKG2D on its cytoplasmic domain and the interaction with Dap10, we 
generated three BA/F3 cell lines with different receptor/adaptor combinations 
depicted in Figure 13. The first NKG2D construct contained a deleted cytoplasmic 
domain in combination with wildtype Dap10 (NKG2D∆cyt DAP10wt). The second 
construct contained a NKG2D with deleted cytoplasmic domain in combination with a 
Dap10 containing an inactivated signaling motif (NKG2D∆cyt Dap10-YF) and the 
third NKG2D variant was mutated in its transmembrane domain: arginine 66 was 
substituted with alanine abolishing the interaction of NKG2D and Dap10 (NKG2D-
RA). Additionally, Dap10 was not transfected in the BA/F3 NKG2D-RA mutants in 
order to reduce possible adaptor interactions. 
 
Figure 13: Schematic representation of human NKG2D/Dap10 constructs on BA/F3 cells. Constructs 
include a NKG2D variant with deleted cytoplasmic domain (NKG2D∆cyt) and a NKG2D variant with an 
arginine to alanine substitution in its transmembrane domain, which is crucial for NKG2D-Dap10 
interaction (NKG2D-RA). In addition, Dap10 constructs include a wildtype variant (DAP10wt) and a 
Dap10 variant with an inactivating tyrosine to phenylalanine substitution in the signaling motif 
(Dap10-YF). 
 
Both NKG2D∆cyt constructs were highly expressed on transfected BA/F3 cells 
(Figure 14A). In contrast, the expression of NKG2D-RA on the cell surface of BA/F3 
cells was reduced, as was expected by the abolished NKG2D-Dap10 interaction. 
Nevertheless, we performed sucrose density gradients with these cells and checked 
for proper DRM recruitment. The results of these assays are shown in Figure 14. 
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As with 2B4, NKG2D is excluded from the DRM fractions if unstimulated, but is 
recruited into the DRM fractions upon stimulation [144]. These results could be 
confirmed. The same is true for NKG2D with a deleted cytoplasmic domain, but 
functional signaling motif in Dap10, which is recruited into the DRMs upon stimulation 
(Figure 14B, C). Even with a disabled signaling motif in Dap10 in combination with a 
deleted NKG2D cytoplasmic domain, NKG2D can be recruited into DRMs upon 
stimulation (Figure 14D). 
 
Thus, neither the cytoplasmic domain of NKG2D nor the signaling functions of Dap10 
seem crucial for lipid raft recruitment of NKG2D. In addition, although weak, NKG2D 
can be detected in the DRM fraction without interaction with Dap10 (Figure 14E), 
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Figure 14: Surface expression of NKG2D constructs on BA/F3 cells and representative Western blots of 
sucrose density gradient fractions (n=4). (A) BA/F3 cells were stained with an NKG2D-specific antibody 
(bold lines) or with an isotype matched control (shaded). All histograms are presented as % of Max. (B-
E) Unstimulated NKG2D∆cyt DAP10wt (B) and stimulated NKG2D∆cyt DAP10wt (C), NKG2D∆cyt 
Dap10-YF stimulated (D) and NKG2D-RA stimulated (E) constructs were tested DRM recruitment. 
Samples were either stimulated by NKG2D crosslinking for 10 min at 37°C (x-link) or left unstimulated 
with a control antibody at 4°C (no x-link). Cells were then lysed and applied to the sucrose density 
gradient. Gradients were fractionated and then applied to Western blotting. Membranes were analyzed 
for NKG2D, Fyn as lipid raft marker and CD45 as non-raft marker with specific antibodies. 
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indicating, that other factors, apart from Dap10 interaction, mediate raft recruitment 
of NKG2D. The reduced signal might be due to the very low surface expression of 
NKG2D in case of NKG2D-RA (Figure 14A). Future studies will have to clarify if 
amino acids within the NKG2D cytoplasmic tail are involved in raft recruitment of this 
molecule.  
 
3.2 Inhibition of Siglec-7 by sialic acid-based inhibitors 
3.2.1 Development of Siglec-7 inhibitor 
Siglec receptors are inhibitory receptors recognizing sialic acid residues. They have 
been implicated in regulation of immune cells, including NK cells, and shown to be 
involved in several malignancies. Siglec-7 is the major Siglec receptor on NK cells, 
but so far, no functional inhibitor for this receptor is available. Therefore, in 
collaboration with the lab of Prof. Brossmer (Biochemistry Center, Heidelberg 
University, Heidelberg, Germany) our aim was to develop an effective Siglec-7 
inhibitor. The inhibitors were synthesized in the laboratory of Prof. Brossmer and 
subsequently tested by us for the ability to inhibit the interaction of Siglec-7 with its 
ligands. In order to detect the interaction of Siglec-7, we made use of a Siglec-7 RBC 
binding assay previously described [97] and modified it to fit our purpose.  
 
RBCs were used as sialic acid presenting platforms and Siglec-7-Fc chimeras were 
used to bind the Siglec-7 ligands among these sialic acids (Figure 15A). RBCs could 
be stained for Siglec-7 ligands as shown in Figure 15B. This staining was specific for 
the binding ability of Siglec-7, as shown by the decrease of Siglec-7-Fc staining 
mediated by a block with Siglec-7-specific antibody (Figure 15C). Inhibitors were 
designed on the basis of the structure of 2-alpha-O-methyl sialic acid (Figure 15D), 
referred to in this work as unmodified sialic acid or compound 37 (see tables) for 
simplicity reasons. Briefly, potential inhibitors were tested by pre-incubation with the 
Siglec-7-Fc chimera prior to incubation of the mixture with RBCs (step I, Figure 15A). 
Bound Siglec-7-Fc chimeras were detected by incubation with biotin-labeled goat-α-
human IgG (step II, Figure 15A), followed by incubation with PE-labeled streptavidin 
(step III, Figure 15A). If the inhibitor was able to impair the Siglec-7 interaction with 
its ligands, the staining in the assay was decreased, as shown in Figure 15E. 
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Figure 15: Basis of Siglec-7 inhibition assay on RBCs. (A) Schematic representation of Siglec RBC 
binding assay.  Reagents are depicted below the scheme. (B) Expression of Siglec-7 ligands on red 
blood cells (RBCs). Effect of α-Siglec-7 antibody (C) or a Siglec-7 inhibitor (E) on Siglec-7-Fc binding to 
RBCs. Shaded histograms represent an unstained control without Siglec-7-Fc protein. (D) Structure of 
2-alpha-O-methyl sialic acid (2-alpha-O-methyl-N-Acetylneuraminic acid, alpha-O-Me Neu5Ac).  All 
histograms are presented as % of Max. 
Siglec ligand                       Siglec-Fc                         Inhibitor               α-human-biotin             Streptavidin-PE 
RBC 
I II III 
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By testing different modifications of the original structure, we were able to improve 
the potential of the inhibitors stepwise. The modification at position 9 of sialic acid 
with different residues led to an increase in inhibitory potential of the inhibitors as 
shown in Figure 16. One of the most effective members of the inhibitors modified at 
position 9 is shown in blue in Figure 16A and C and table 2. Compared to unmodified 
sialic acid (shown in red) this inhibitor was up to ten times more efficient in the 
inhibition assays and showed IC50 values in the lower millimolar range. 
 
 
 
 
 
Figure 16: Development of Siglec-7 inhibitors, part I. (A) presents early substances used to inhibit 
Siglec-7. Unmodified sialic acid (red), compound 27 (blue) and compound 112 (cyan) are depicted in 
structure together with IC50 values and relative inhibitory potential (rIP) compared to unmodified sialic 
acid. (B) shows compound 112 at the ligand-binding pocket of Siglec-7 in a modeling study performed 
by Dr. Martin Frank (Biognos AB, Göteborg, Sweden). (C) presents the mean inhibition (± SD) of Siglec-
7 ligand interaction at different concentrations mediated by all three compounds in RBC binding assays. 
Data are representative of at least three independent experiments. % inhibition was calculated as 
explained in Materials and Methods. 
Results   63 
Further modification at this position, including those of the published oxamido 
inhibitor [97], led to improvements of inhibitory potentials (table 3). Later 
modifications were performed at position 2, as this position was predicted to enable a 
good fit of the inhibitor into the binding site. The most efficient modification at position 
2 was the addition of a biphenyltriazolpropyl residue (Figure 16, cyan) that caused a 
152-fold increase in inhibitory potential compared to sialic acid and achieved an IC50 
in the micromolar range (Figure 16A and C, table 4). Docking studies supported the 
notion that this long and flexible modification enabled the inhibitor to fit into the cavity 
of tyrosine 64 within the binding groove of Siglec-7, as shown in Figure 16B. 
 
 
Figure 17: Development of Siglec-7 inhibitors, part II. (A) presents late substances used to inhibit 
Siglec-7. Unmodified sialic acid, compound 112 (blue) and compound 118 (red) are depicted in structure 
together with IC50 values and relative inhibitory potential (rIP) compared to unmodified sialic acid (white). 
(B) shows compound 118 at the ligand-binding pocket of Siglec-7 in a modeling study performed by Dr. 
Martin Frank (Biognos AB, Göteborg, Sweden). The mesyl group of compound 118 is shown in 
neighborhood of lysine 135 and arginine 23 of Siglec-7 and the biphenyl tail is shown in the tyrosine 64 
cavity. (C) presents the mean inhibition (± SD) of Siglec-7 ligand interaction at different concentrations 
mediated by the compounds 112 and 118 in RBC binding assays. Data are representative of at least 
three independent experiments. 
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Additional improvements in inhibitory potential were sought through the modification 
of this substance at position 9 of the sialic acid structure. One of the most potent 
substances was modified at position 9 with a mesyl group as shown in red in Figure 
17A and table 11. This substance achieved an IC50 in the lower micromolar range, 
which corresponds to a 3167-fold increase in inhibitory potential compared to 
unmodified sialic acid (Figure 17A and C). This improvement was most likely due to 
the possible formation of interactions between the mesyl group of the inhibitor and 
lysine 135 and arginine 23 of the receptor as shown in Figure 17B, which depicts 
docking of the mesyl group of the inhibitor between lysine 135 and arginine 23.  
 
Although we generated more potent inhibitors by now (table 10), we decided to test 
compound 118 for functional effects on human NK cells at this point. Thus, in the 
further course of this thesis, the Siglec-7 inhibitor used refers to this compound. An 
excerpt of all substances tested so far is presented in tables 1 - 11 with their relative 
inhibitory potentials. 
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3.2.2 Functional effects of sialic acid-based inhibitor on NK cells 
In the next step, we wanted to know whether the Siglec-7 inhibitor showed effects on 
the function of human NK cells. We choose 51Cr release assays in order to analyze 
NK cell activity, the killing of target cells. First, we screened target cell lines for a 
suitable expression of Siglec-7 ligands. From this screening, the two cell lines, the 
erythroleukemic K562 and the melanoma cell line Mel1106 were selected due to their 
expression profile (Figure 18A-C).  
 
K562 cells express a moderate amount of Siglec-7 ligands (Figure 18A) whereas 
Mel1106 cells express Siglec-7 ligands to a lower extent (Figure 18B). In accordance 
with the literature [104, 107], Mel1106 express the high affinity Siglec-7 ligand GD3 
(Figure 18C). In addition, all NK cells used for the 51Cr release assays were tested for 
Siglec-7 expression, a representative staining is shown in Figure 18D.  
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Figure 18: Expression of Siglec-7 ligands and Siglec-7 on cells used in 51Cr release assays. Siglec-7 
ligand expression on K562 (A) and Mel1106 (B) cells. High affinity Siglec-7 ligand GD3 expression is 
shown in C. Expression of Siglec-7 on NK cells is shown in D. Shaded histograms represent control 
stainings without Siglec-7-Fc fusion protein (A-B) or isotype controls (C-D). All histograms are presented 
as % of Max. 
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K562 cells were first tested as target cells in the 51Cr release assay due to their 
higher Siglec-7 ligand expression and their common use as target cells for NK cells 
in these assays.  
 
 
The inhibitor (compound 118, table 11) was tested for its efficacy in the assay. 
Unmodified sialic acid was used as a control (compound 37). IL-2-activated primary 
human NK cells were used as effector cells throughout the 51Cr release assays. To 
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Figure 19: 51Cr release 
assays with Siglec-7 inhibitor. 
IL-2-activated human NK 
cells were pre-incubated with 
0.3 mM Siglec-7 inhibitor or 
unmodified sialic acid or 
medium alone preceding 
coincubation for 4 h at 37°C 
with 51Cr-labeled target cells. 
Values represent mean 
specific lysis ± SD of 
triplicates of representative 
51Cr release assays. A 
representative assay with 
K562 target cells is shown in 
A (n = 3). Representative 
assays with Mel1106 target 
cells are shown in B and C 
(n = 5). 
 
B 
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our surprise, the Siglec-7 inhibitor did not increase the lysis of K562 cells in 
comparison to sialic acid alone or a medium control (Figure 19A).  
In order to exclude a cell line specific effect, as K562 cells are extraordinary 
stimulatory for NK cells and thus might override weak inhibition signals, we 
performed the 51Cr release assays with the Mel1106 cells, which are much more 
resistant to NK cell mediated lysis. As expected, the lysis of Mel1106 target cells was 
lower than that of K562 cells. Interestingly, we found a small increase in lysis of the 
Mel1106 target cells as shown in Figure 19B, but this was only the case in about half 
of the experiments. The other assays with the Mel1106 cells with the same 
conditions did not show any effect on the killing of the target cells (Figure 19C). Thus 
the inhibitor was able to achieve an improved lysis of the target cells although not in 
all experiments. 
 
3.2.3 Factors influencing Siglec-7 inhibitor efficacy 
It has been previously published that Siglec-7 shares some ligand specificity with its 
relative Siglec-9 that shares 84 % structure homology with Siglec-7 [91, 94, 95]. Both 
of these Siglec receptors have been described to be expressed by human NK cells. 
Thus, the questions arose whether the developed Siglec-7 inhibitors affected Siglec-
9 as well and whether this interaction was the basis for observed functional effects. 
Human NK cells were analyzed via flow cytometry for their expression profiles of 
Siglec-7 and Siglec-9 (Figure 20A, B). In all experiments, the staining of Siglec-7 on 
the NK cells was higher than that of Siglec-9. The antibodies used were assessed via 
ELISA for their affinity towards Siglec-7 and Siglec-9 in order to enable a correlation 
of the flow cytometry data with the amount of Siglec expression. In those assays the 
α-Siglec-9 antibody showed a higher affinity (data not shown), which supports the 
conclusion drawn from the FACS data that Siglec-7 is more abundant on the surface 
of human NK cells. In another attempt to investigate the effect of the Siglec-7 
inhibitor on Siglec-9, we applied a modified Siglec-7 inhibition assay. Instead of 
RBCs, which only express Siglec-7 ligands, K562 were used as sialic acid platforms 
as they expressed ligands for both, Siglec-7 and Siglec-9 (Figure 20C). Siglec-7-Fc 
and Siglec-9-Fc fusion proteins were incubated with the Siglec-7 inhibitor and, as 
with the previous Siglec-7 inhibition assays, the reduction of binding was determined 
by flow cytometry. Those experiments showed that the interaction of Siglec-7 with its 
ligands was about 100-fold more sensitive to the inhibitor than the interaction of 
Siglec-9 with its ligands (Figure 20D). These data supported our hypothesis that the 
observed effects were due to an inhibition of Siglec-7 and not Siglec-9. 
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Figure 20: Specificity of compound 118 against Siglec-7-Fc & Siglec-9-Fc. Expression of Siglec-7 (A) or 
Siglec-9 (B) on NK cells used in 51Cr release assays. Shaded histograms represent isotope controls. (C) 
Expression of Siglec-7 ligands (black) and Siglec-9 ligands (gray) on K562 used for comparison of 
inhibitor specificity. Shaded histogram represents unstained control without Siglec-Fc. All histograms 
are presented as % of Max. (D) Inhibition of Siglec binding by different concentrations of the Siglec-7 
inhibitor (n=3). 
 
Another possibility for inaccurate results of Siglec-7 inhibition on NK cells is a 
potential toxicity of the inhibitor that might influence the lysis of cells during the 51Cr 
release assays.  
In those assays, a lysis of target cells in the presence of the inhibitor alone could not 
be detected (data not shown), but the toxicity towards the NK cells could not be 
assessed with these assays. To this end, NK cells were incubated in the presence of 
the inhibitor at various concentrations and afterwards analyzed for apoptosis by a 
living/dead analysis using Annexin-V and 7-AAD (Figure 21A-C). Annexin-V binds to 
phosphatidylserine that is only present on the cell surface, if the cell enters apoptosis 
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and is unable to sustain membrane integrity. 7-AAD is a membrane-impermeable 
DNA-intercalating agent, which stains DNA once the cellular membranes 
disintegrate. From these stainings, cells can be classified as healthy (Annexin-V-/ 7-
AAD-), early apoptotic (Annexin-V+/ 7-AAD-) or late apoptotic (Annexin-V+/ 7-AAD+). 
The incubation of the NK cells with the inhibitor did not result in an increased amount 
of apoptotic cells at the applied concentrations as shown in Figure 21.  
A
 
B 
 
C
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Figure 21: Toxicity of Siglec-7 inhibitor on primary human IL-2 activated NK cells. NK cells were 
incubated for 24 h at 37°C with medium alone (neg. control) or different concentrations of the Siglec-7 
inhibitor or an ATP-depleting apoptosis-inducing agent (positive control). NK cells were then stained for 
Annexin-V binding and 7-AAD and classified into early apoptotic (AnnexinV+/7-AAD-) or late apoptotic 
(AnnexinV+/7-AAD+) events. Representative blots of negative control, positive control and 10’000 µM 
Siglec-7 inhibitor are shown in (A-C). (D) presents statistics of three independent experiments. 
 
According to these data, a side effect of toxicity could be dismissed. Thus, we 
generated a specific inhibitor capable of a potent block of the ligand binding of 
Siglec-7.  
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4 Discussion 
4.1 Lipid raft recruitment of activating NK cell receptors 
4.1.1 Lipid raft recruitment of the SLAM-related receptor 2B4 
Using a mutagenesis approach we analyzed the DRM recruitment of the human 2B4 
for its molecular requirements. The implication of these observations has to be 
regarded with care as the data were obtained with a sucrose density gradient and 
cannot be translated directly to an identical role in the physiology of NK cell lipid 
rafts.  
Indeed, there has been an intense debate over the existence of lipid rafts and the 
methods applied to study them [161]. These critical remarks concerning lipid rafts are 
not without basis. Several points have to be regarded concerning the applied 
detergent extraction with sucrose density gradients. During the detergent extraction, 
the membranes are kept at 4°C which is not the physiological temperature for cellular 
membranes. As lipid membranes are temperature sensitive, this reduction in 
temperature might cause changes in the obtained membrane fractions by itself. In 
addition, the use of the detergent Triton X-100 to solubilize non-raft membranes is 
not without cruces as it is not entirely sure, whether the detergent only removes the 
non-raft part of the membrane.  
Several studies reported observations that might challenge this assumption of simple 
phase separation [161]: For example, the two leaflets might mix upon detergent 
extraction and thereby change the composition of the obtained DRMs; the detergent 
resistance of outer and inner leaflet may vary and cause a membrane solubilization 
divergent from the predicted one. Moreover, only particular proteins might be 
extracted depending on their physical properties from the membrane and this might 
change the DRM composition [187]. There is a whole range of factors that might alter 
the final composition of the obtained DRMs; therefore the DRM fractions should not 
be mistaken for an exact equivalent of lipid rafts in the living cell. Additionally, as can 
be seen from the DRM fractions in Figure 6 and Figure 8, the assays can vary 
drastically in their appearance; thereby hindering the exact quantification of such 
assays. 
On the other hand, data obtained from these assays should not be regarded as false 
or unfeasible. Obviously, the localization of membrane components in these assays 
is not random: GPI-anchored proteins were shown to be enriched in DRMs [166] as 
are other proteins with different modifications, e.g. palmitoylation [163]. Therefore, 
specific interactions seem to underlie these observations of membrane segregation. 
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With increasing data supporting the presence of lipid rafts [162], also the data 
obtained by detergent extraction become more meaningful.  
Altogether, residence of proteins in DRMs should be regarded as indication for a 
possible association of the proteins with lipid rafts. Whether this is the case has to be 
confirmed with experiments in more physiological membranes or preferentially in 
living cells. The fact that small changes in the studied mutant receptors caused 
severe and reproducible changes in the DRM recruitment of these molecules 
supports the significance of these data. 
The observation of a complete loss of DRM recruitment upon the exchange of the 
2B4 transmembrane domain with the transmembrane domain of LAT is surprising, as 
lipid raft association similar to the constitutive palmitoylation-dependent lipid raft 
localization of LAT was expected. The obvious difference might be due to a lack of 
sequences regulating the palmitoylation of the LAT transmembrane domain as a 
successful palmitoylation also depends on the surrounding structure of the target 
amino acid. For example, the common presence of hydrophobic amino acids and 
prenylation or myristoylation sites adjacent to the palmitoylation site has been 
described [188]. The reason why our construct does not localize into the DRM 
fraction might be due to a too short replacement domain from LAT, which is devoid of 
these regulatory structures for palmitoylation. In order to circumvent this problem we 
exchanged a bigger portion of the LAT transmembrane domain or a transmembrane 
domain of a FcγRIIA mutant described to constitutively localize into lipid rafts [184]. 
Neither of these mutants was localized into the DRM fraction (data not shown). Either 
these mutants were also insufficient to enable palmitoylation, or palmitoylation of 
h2B4 alone is insufficient to mediate DRM recruitment. Still, the complete loss of 
DRM recruitment upon transmembrane domain exchange highlights the importance 
of this domain for the lipid raft recruitment of h2B4.  
In addition, we observed a crucial requirement of a CxC motif in the transmembrane 
domain of human 2B4 for the recruitment of the receptor into DRMs after cross-
linking (Figure 10). This requirement of the h2B4 is consistent with published data for 
the murine 2B4 (m2B4), which is also dependent on this motif for DRM recruitment 
[185]. In contrast to the transmembrane domain, the cytoplasmic domain of h2B4 
(including the signaling motifs) was dispensable for the recruitment into DRMs after 
cross-linking (Figure 6). Previous studies proposed that h2B4 is first recruited into 
lipid rafts and then phosphorylated [124]. Our observation that the deletion of the 
cytoplasmic domain of h2B4 does not affect the DRM recruitment supports the notion 
that lipid raft recruitment is independent of receptor phosphorylation and occurs first. 
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Thus, the possibility that a signaling partner, recruited after h2B4 phosphorylation, 
mediates the lipid raft recruitment of h2B4 is very unlikely. 
The exact properties of the CxC motif are not resolved though. Different 
modifications and interactions can recruit a protein to lipid rafts: Cholesterol- and 
sphingolipid-binding and/or association have been described to affect lipid raft 
association [168-170]. These sphingolipids modifications are unlikely in case of the 
CxC motif, though, as sphingolipids mainly reside in the outer leaflet of the 
membrane whereas the CxC motif is located at the boundary of the cytoplasmic side. 
The same is true for GPI-anchors, which are enriched in the outer leaflet [189]. 
Cholesterol is present in the inner leaflet of the plasma membrane as well, and thus 
might be harnessed by binding or association though. Still, modifications or 
interactions at the inner leaflet of the membrane appear more reasonable due to the 
location of the CxC motif in the transmembrane domain. One modification, which has 
been shown to increase association with lipid rafts through the inner leaflet, is S-
acylation, more specifically the palmitoylation of proteins [163] as found in the CxxC 
motif of LAT [183] or the CxC motif of Lck [190] which is intriguingly similar to the 
CxC motif of h2B4.  
Using the palmitoylation prediction software CSS-Palm [186], we could confirm the 
CxC motif as a potential palmitoylation site in h2B4. However, our attempt to inhibit 
palmitoylation with 2-bromopalmitate, an established palmitoylation inhibitor [191], 
did not result in feasible data (data not shown). The labeling of h2B4 with radioactive 
palmitate did not result in feasible data either ([124], data not shown and personal 
communication). A better way to study possible protein palmitoylation has emerged 
in the last years in the field of click chemistry [192] which enables the specific 
detection of palmitoylated proteins.  
Click chemistry includes the modification of substances with simple, small units. The 
most prominent example of such a Click reaction is the Huisgen cycloaddition. In this 
reaction, an azide-labeled substance reacts with an alkyne and forms a triazole ring 
that covalently links both original substances [193]. These reactions and their 
products are stereospecific, physiologically stable and non-toxic. For example, azide-
labeled palmitates could be fed to cells in order to be incorporated by those. 
Subsequently, the cells would be lysed and immunoprecipitated for the protein of 
interest. In another step, the Click reaction could be performed with an alkyne-
labeled detection reagent in order to determine palmitoylation of the 
immunoprecipitated protein. The application of such methods will surely provide 
further inside into the modifications of lipid raft-associated proteins.  
76   Discussion 
Interestingly, a palmitoylation of m2B4 could not be detected in a previous study 
(data not shown) [185]. This should not be taken into account towards a similar 
behavior of h2B4 though, as differences between lipid raft behavior of h2B4 and 
m2B4 emerged in previous studies: For example, h2B4 was shown to localize into 
DRM only after cross-linking ([124] and Figure 5) whereas m2B4 was constitutively 
resident in DRMs [185]. In general, palmitoylation should not be regarded as an 
exclusively permanent modification that results in constitutive effects though. 
Palmitoylation of proteins has also been described to be of transient nature [194] and 
crosslinking h2B4 might induce its palmitoylation lasting only for a given time, e.g. 
the duration of a stimulatory cell contact. Although this might also be an effect 
caused by the used cell lines (e.g. due to different extents of cis-interactions of 2B4 
with CD48), rather than the receptor, the behavior of m2B4 should not be put on the 
same level as the behavior of h2B4. Further analysis is thus required to elucidate the 
underlying causes. 
Another possibility is that h2B4 associates with another protein via the CxC motif, 
and that this association mediates lipid raft recruitment of h2B4. Such an association 
would occur prior to the phosphorylation of the ITSMs, as raft recruitment is 
independent of ITSM phosphorylation (see 2B4-YF in Figure 6), and therefore signal 
transduction of h2B4 as well. The association either has to be induced prior to ITSM 
phosphorylation or be constitutive.  
Interestingly, in this context, two previous studies described a constitutive association 
of LAT with h2B4 [195, 196]. This association may either be direct or mediated by the 
shared residence in lipid rafts. These studies immunoprecipitated LAT with h2B4, but 
the possibility that the association observed in these studies is mediated by a shared 
residence in resistant membrane fractions still remains. A similar observation of 
association with LAT was made for m2B4 and this association of m2B4 with LAT was 
dependent on the CxC motif [185]. Therefore, h2B4 might associate with LAT via this 
CxC motif as well.  
In support of this notion, an interaction of LAT with the co-receptors CD4 and CD8 
via a similar CxC motif in the co-receptors has been shown [197]. Additionally, an 
interaction of both co-receptors with the protein tyrosine kinase Lck mediated by the 
same motif has been described previously [198, 199]. Therefore, such a CxC motif 
might be used for protein association in the immune cells. The existence of such an 
association with LAT via the CxC motif in h2B4 surely has to be studied in detail and 
hopefully will shed light into the combination of lipid raft recruitment and signal 
transduction of 2B4.  
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If this interaction between h2B4 and LAT holds true, this raises the question, whether 
h2B4 might mediate other associations with this motif as well. As mentioned 
previously, LAT can associate with CD4 and CD8 via this motif while both co-
receptors can associate with Lck. Therefore, an association of h2B4 with Src-family 
kinases with a similar CxC motif might be possible. The associative potential and 
regulation of interactions via this CxC motif in h2B4 have to be resolved in future 
studies.  
The question arises whether LAT is required for the lipid raft recruitment of 2B4. All 
previous studies determining the DRM recruitment of 2B4, including this one, made 
use of cell lines expressing LAT [124, 185] which is consistent with the physiological 
situation as 2B4 is predominantly expressed in LAT expressing cells. A potential 
dependency of lipid raft recruitment could be analyzed either by LAT deficient cells or 
by the use of gene knockdown methods. Support for the importance of LAT for 2B4 
is found in murine lymphokine-activated killer (LAK) cells, where LAT deficiency was 
shown to cause a reduction in 2B4-mediated cytotoxicity [185]. Whether such 
functional impacts are also the case for 2B4-mediated cytotoxicity in human NK cells 
is unknown. 
Of course, other mediators of lipid raft recruitment might associate with h2B4 via the 
CxC motif as well. Although there is no data about signal-independent associations 
of proteins with h2B4 apart from LAT, it is known that the lipid raft recruitment is 
dependent on an intact cytoskeleton [124].  
A crucial role of the cytoskeleton for lipid raft regulation has been also shown in other 
cell types as T cells [174] and cytoskeleton-related proteins like ezrin, radixin, moesin 
(ERM) proteins are present in the DRM fractions of immune cells, e.g. of T cells [174, 
200]. It is not known though, whether the requirement of an intact cytoskeleton lies 
on the active recruitment of the receptors into lipid rafts and thus the formation of 
lipid rafts, or whether the cytoskeleton is only required to stabilize the lipid raft. The 
fact that an h2B4 mutant without cytoplasmic domain is able to migrate into the DRM 
fraction makes an interaction of the cytoskeleton or linking proteins through this part 
of h2B4 unlikely. It has to be considered though that the crosslinking of h2B4 with 
antibodies on the extracellular side might substitute for a cytoskeleton-mediated 
arrangement of h2B4 in our assays. The cytoskeleton should thus not be neglected 
as a potential mediator in initial lipid raft recruitment of h2B4. 
Additionally, the possibility remains that a protein associating via the CxC motif 
mediates a connection to the cytoskeleton. The regulation of lipid raft stability by the 
cytoskeleton has been shown in different studies and models: A picket-fence model 
was proposed in which an actin network below the plasma membrane influences the 
78   Discussion 
organization and stability of lipid rafts [201]. In addition, an intact cytoskeleton was 
required for the exclusion of lipid rafts from iNKIS [179]. Moreover, the reorganization 
of the actin fibers at the NKIS is one of the first steps induced during synapse 
formation [44] and this reorganization might affect the coalescence of lipid rafts in 
active or passive ways. Therefore, the cytoskeleton seems to hold lipid rafts together 
and at the required location; whether it also mediates the active recruitment of lipid 
raft-associated receptors remains to be seen. 
 
Another observation made from our experiments was that the amino acids of the 
h2B4 transmembrane domain most likely resident at the extracellular side of the 
membrane also influence the DRM recruitment of h2B4 (Figure 8); although this 
effect was not as strong as the one observed for the CxC motif.  
Upon further examination we could pinpoint this effect to the FLVIIVILS sequence in 
the transmembrane domain (Figure 12). The strongest effect on DRM recruitment by 
mutation in this region was mediated by the FLV and ILS sequences. These amino 
acids are not adjacent but separated by the amino acids IIV. The most common 
structural element used by proteins to span a membrane is the α-helix [202]. It is 
preferential in its orientation as it directs the hydrogen bonds of the peptide backbone 
to the internal side. Thereby it reduces the extent of polar groups at the lipid-protein 
interface, which might interfere with the alignment of the transmembrane domain. In 
an α-helix, every N-H group forms a hydrogen bond with every C=O group four 
amino acids earlier in the helix and therefore every four amino acids are placed on 
top of each other. This fits with the gap formed by the IIV between FLV and ILS. 
Therefore, the positioning of the FLV one helix turn over the ILS might form a 
structure important for the DRM recruitment of h2B4. 
It is also of note that this segment is mostly formed by hydrophobic amino acids. A 
similar requirement for the presence of hydrophobic amino acids in the luminal side 
of the transmembrane domain for lipid raft association has been observed for the 
viral transmembrane protein hemagglutinin (HA) [203].  
In fact, the association of proteins with membrane lipids has previously been 
described as a means to increase lipid raft association and is regarded as a 
fundamental interaction for membrane heterogeneity [162]. This so-called ‘wetting’ or 
‘lubrication’ describes the association of a protein (but not necessarily the binding) 
with a lipid. The lipid-facing surface of a membrane protein is formed by grooves and 
protrusions which can provide low specificities for certain lipids [204]. Although 
transmembrane domains of proteins are regarded to reside stiffly in the membrane, it 
was proposed that lipids can be distorted to better fit the specific structure of a 
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transmembrane domain [172]. Therefore, certain lipids would show a better 
associative capacity than others, which is underscored by the vast repertoire of 
different lipids abundant in cellular membranes [205].  
This specificity could even be improved by the combination of different proteins with 
lipid associative potential. For example, receptor clustering or oligomerization could 
capture matching lipids, which then would influence the lipid raft association of the 
receptor cluster [162, 204]. This behavior has been shown for caveolin that, as an 
oligomer, contains a cholesterol-binding groove [169]. The reduced capability of 
h2B4 to localize into DRM fractions upon mutation of specific amino acids at the 
luminal side of the transmembrane domain might be due to a decreased association 
potential of the transmembrane domain with raft-associated membrane lipids or due 
to unknown protein interactions at the outer leaflet. Although the 2B4 structure has 
been analyzed in previous studies, the focus of these studies was on the 
extracellular ligand binding domains [206, 207]; there is no data available about the 
structure of the 2B4 transmembrane domain that might allow a more detailed 
analysis of possible lipid-receptor association.  
In addition, the binding of lipids as cholesterol or sphingolipids to a protein can 
influence membrane localization as well. The modification of a protein with 
cholesterol and palmitates can link a protein to a membrane, as seen in the protein 
family hedgehog [175, 208]. Additionally, a range of sphingolipids-binding domains 
has been described in the last years that allow a transmembrane protein to bind 
sphingolipids and thereby alter their lipid raft association [168, 170]. Such binding 
sites might exist in the transmembrane domain of h2B4 and assist in the lipid raft 
recruitment of h2B4 upon ligation, but whether the FLV and ILS sequences in the 
transmembrane domain of h2B4 form such a cholesterol- or sphingolipids-binding 
site has to be solved in future work.  
 
It is also a compelling finding that the cytoplasmic domain of h2B4 with replaced 
extracellular and transmembrane domains (and therefore without the CxC motif and 
FLV/ILS) is sufficient for phosphorylation of 2B4 and subsequent signaling [209]. If 
an association of h2B4 with lipid rafts occurs via the transmembrane domain, this 
would indicate an interesting divergence between the mechanism for lipid raft 
recruitment and the mechanism for signal transduction. As mentioned previously, 
LAT deficiency in murine LAK cells was shown to impair 2B4-mediated cytotoxicity 
[185]. Whether this is due to impaired raft recruitment or the lack of a signaling 
component remains to be shown. It was previously described that LAT is 
phosphorylated after the phosphorylation of h2B4 [195].  
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Additionally, phosphorylated h2B4 was only detected in DRM fractions and DRM 
recruitment of h2B4 is Src-family kinase dependent [124]. As the DRM recruitment of 
h2B4 is Src-family kinase dependent and h2B4 does not rely on its cytoplasmic 
domain for DRM recruitment, the phosphorylation of other mediators is necessary to 
mediate the lipid raft localization of h2B4. This might either be the regulation of lipid 
raft stability by the cytoskeleton, in this case maybe ERM proteins or related proteins, 
or the active recruitment of h2B4 by a yet unidentified component. Taken together, 
these data imply that LAT is phosphorylated in the lipid rafts after h2B4 has been 
recruited there.  
 
From our data we draft the following hypothesis based on the current lipid raft model 
[175]: 
In the resting state, the receptor 2B4 is resident in the non-raft phase of the 
membrane (Figure 22A). The affinity towards more ordered nanodomains may be 
increased by weaker forces, e.g. by a lipid modification at the luminal 
transmembrane domain sequence FLVIIVILS or by the association of this domain 
with lipids. These nanodomains are probably not big enough to withstand detergent 
extraction though. Upon ligation of the receptor, these nanodomains may be 
clustered leading to larger nanodomains (Figure 22B). Subsequently, these will 
coalesce into a macrodomain (Figure 22C), if the stimulus is sufficient (e.g. by an 
aNKIS). The recruitment of the smaller nanodomains containing 2B4 into this 
macrodomain is cytoskeleton-dependent [124]; either due to active transport or to 
stabilization of the lipid raft. The recruitment additionally is dependent on the CxC 
motif in the transmembrane domain of 2B4. The underlying cause might be a 
modification, as palmitoylation, or the association with a lipid raft associated 
component, e.g. LAT. The effects of lubrication and the CxC motif are probably not 
mutually exclusive though. The CxC motif might assist in small nanodomain 
association whereas the lubrication might also favor large nanodomain formation. 
The transit from small nanodomains into larger domains might also mark the 
development of a detergent resistance and include a positive feedback loop. Such a 
feedback loop could involve initial signals (e.g. via Vav-1), which induce or stabilize 
nanodomains recruitment by means of cytoskeletal remodeling. This would cause 
larger nanodomains to recruit more small nanodomains in order to form a 
macrodomain. In these macrodomains or so-called lipid rafts, 2B4 is phosphorylated 
by resident Src-family kinases. This step then initializes the signal transduction 
through 2B4 by recruitment of SAP and 3BP2 and subsequent signaling partners 
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[57]. During this signaling process, LAT is phosphorylated as well [195]. Ultimately, 
this process will then result in cytotoxicity and/or cytokine secretion of the NK cell.  
 
 
Figure 22: Schematic illustration of our model of 2B4 lipid raft 
recruitment. (A) presents the resting state. 2B4 dynamically 
moves in and out of small raft nanodomains (A-I). The 
association with such nanodomains may be increased by 
modifications of 2B4, as lubrication (A-II). (B and C) depict 
mechanisms induced by receptor ligation. (B) Small raft 
nanodomains coalesce into larger nanodomains upon 2B4 
ligation. This is dependent on an intact cytoskeleton and the CxC 
motif at the cytoplasmic transmembrane domain of 2B4. The 
dependence on the CxC motif might be due to palmitoylation (B-I) or association with a raft-resident 
molecule as LAT (B-II). (C) Raft macrodomains are formed from the nanodomains at the aNKIS. 2B4 is 
phosphorylated in this domain by raft-resident Src-family kinases and transduces an activating signal 
into the NK cell. 
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Especially the lack of detailed data for the transmembrane domain of 2B4 should be 
approached in order to obtain a better understanding of mechanism mediated by this 
domain. The involvement of the cytoskeleton in the initial lipid raft recruitment of 
h2B4 should be clarified. A more physiological approach with cell-cell contacts 
should be applied to circumvent potential effects mediated by the extracellular 
clustering via antibodies. Several modifications are also known to influence lipid raft 
association of a membrane protein and these should be studied more closely: A 
putative palmitoylation of h2B4 has to be resolved, e.g. by click chemistry. Potential 
interaction via the CxC motif with other membrane components has to be analyzed. 
Additionally, the importance of the CxC motif could be analyzed via a knock-in 
mutant with a mutated LACFCV domain but functional CxC motif. The study of the 
binding capacity to different components with mutants of the CxC motif seems 
reasonable; additionally the capacity of h2B4 to migrate into DRMs in dependency of 
these components should be analyzed. The effect of the luminal transmembrane 
sequence FLVIIVILS should be studied as well as lipid associations and 
modifications of proteins at the outer membrane leaflet have been described to 
mediate lipid raft association. Therefore, modification of the 2B4 transmembrane 
domain with lipid species should be analyzed applying chemical methods as click 
chemistry or bioinformatic approaches. The putative association of lipids could be 
studied by a better resolution of the 2B4 structure, with a focus on the 
transmembrane domain, and modeling studies to gauge the surface of the 2B4 
transmembrane domain for grooves and protrusions that allow putative association 
with specific lipid species. 
 
Overall, this work has expanded the knowledge about the 2B4 transmembrane 
domain and provides the basis for more elucidated work on the mechanisms of lipid 
raft recruitment. In addition, this work was also able to support previous notions 
about mechanisms and requirements of 2B4 lipid raft recruitment. 
 
4.1.2 Lipid raft recruitment of the C-type lectin-like receptor NKG2D 
The function of lipid rafts has previously been described to be obligatory for NKG2D-
mediated activation of NK cells [144] (and data not shown), in agreement with other 
studies showing the importance of lipid rafts for NK cell activation [49, 124]. In 
addition to 2B4, we therefore investigated the basis of the lipid raft recruitment of 
NKG2D. Similar to our approach to analyze molecular mechanisms of 2B4 
recruitment into lipid rafts, we applied a mutagenesis approach with sucrose density 
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gradients to investigate the mechanisms underlying the previously observed lipid raft 
recruitment of NKG2D [144]. The methods applied for this were the same as with the 
2B4 study and therefore every concern mentioned for the 2B4 results also applies for 
the NKG2D data and will not be discussed again. In addition, due to a failure in the 
study no feasible data for the wildtype NKG2D were obtained and thus only 
observations possible from the obtained data are discussed. 
Our data show that NKG2D can be recruited into DRM fractions despite the lack of 
the NKG2D cytoplasmic domain and the signaling capacity of Dap10 (Figure 14). In 
addition, although devoid of an interaction with Dap10 and at far lower surface 
expression levels, minimal amounts of NKG2D could be detected within the DRM 
fraction (Figure 14E). These observations give important clues for the mechanism 
underlying NKG2D raft recruitment: NKG2D is distinct from the above-discussed 
SRR 2B4 as it is a type II transmembrane receptor and does not contain signaling 
motifs as 2B4, but instead associates with Dap10 [136, 138]. Despite these 
differences, NKG2D lipid raft recruitment seems to be independent from signal 
transduction mediating cellular activation, as the tyrosine-based signaling motif of 
Dap10 and the whole cytoplasmic domain were dispensable. This releases the raft 
recruitment of NKG2D from the need to associate with Dap10, PI3K or Grb2, which is 
phosphotyrosine-dependent and required for NKG2D-mediated cytotoxicity [143]. 
Therefore, similar to the data for 2B4, the lipid raft recruitment of NKG2D is likely to 
occur prior to the signal transduction of Dap10. This leaves several alternatives for 
discussion: The transmembrane domain of NKG2D, the extracellular part of NKG2D 
or each domain of Dap10 might assist the lipid raft recruitment. The overall influence 
of Dap10 seems to be rather low as trace amounts of NKG2D could be detected in 
the DRM fractions in absence of Dap10 and with about 30-fold decreased surface 
expression levels of NKG2D. This reduces the possibility of Dap10-mediated effects, 
such as associations with other proteins or modifications as palmitoylation or 
lubrication [162], that might influence NKG2D raft recruitment. Dependent on these 
data, a putative role of Dap10 should not be excluded though yet. The impact of 
Dap10 should be analyzed further to exclude a false interpretation of these sparse 
data.  
Apart from oligomerization upon ligation, a direct effect of the extracellular part of 
NKG2D is unlikely. The transmembrane domain of NKG2D might harbor different 
possibilities for lipid raft recruitment: The first possibility is palmitoylation. Indeed, 
CSS-Palm [186] predicted a positive hit at cysteine 57 in the transmembrane domain 
of NKG2D. It is important to note that such a positive hit does not guarantee a 
palmitoylation at such site. So far, a palmitoylation of NKG2D has not been 
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described. Another possibility is the association with proteins which mediate lipid raft 
recruitment, for example cytoskeleton-associated proteins [174], such as the ERM 
proteins. Apart from the interaction with Dap10 via the arginine at position 66 in the 
transmembrane domain of NKG2D and the aspartate at position 57 of Dap10 [138], 
no direct interaction of NKG2D mediated by its transmembrane domain is known. 
Potential binding motifs as the CxC motif of 2B4 have not been identified in NKG2D 
and NKG2D seems to be regulated independent of transmembrane adaptors, e.g. as 
LAT [142]. A more likely influence on the lipid raft recruitment of NKG2D might be 
mediated by the nonpolar amino acids in the transmembrane domain of NKG2D that 
are located at the interface to the lipids of the membrane. These amino acids define 
possible association or binding sites for lipids and these can influence lipid raft 
recruitment [168]. This alone can influence the lipid raft association of NKG2D, but is 
even emphasized by the quaternary structure of NKG2D: A NKG2D homodimer is 
formed through disulfide-bridges, which associates with two Dap10 homodimers 
[138]. Thereby a single unligated NKG2D receptor complex comprises six 
transmembrane domains with a potential lubrication of each. Such a complex alone 
could trap certain lipids (as seen with other membrane proteins, e.g. caveolin-1 [168, 
169]) and thereby obtain a lipid raft affinity. This would even increase upon ligation of 
the receptor as more ordered membrane is included into this raft by the clustering of 
the receptors. Such an effect of receptor complexes could be analyzed by the 
mutation of the cysteines forming intermolecular disulfide-bridges to alanines, 
thereby breaking the NKG2D complex down into trimers. The DRM recruitment of 
such mutants could be analyzed with the here-applied methods. 
It is also interesting to note that previous studies observed a requirement for an intact 
cytoskeleton for NKG2D (similar to 2B4) to transduce activating signals [144]. 
Therefore, the mechanism underlying NKG2D raft recruitment might be similar to that 
of 2B4 in a general scheme: By the ligation of NKG2D, smaller NKG2D-containing 
nanodomains might be clustered to larger nanodomains with putative first signaling 
capacity. Signaling at this point could influence the cytoskeleton in order to recruit 
more NKG2D-containing nanodomains. In dependence of the cytoskeleton and 
probably a positive feedback loop, a macrodomain with full signaling capacity is 
formed. This macrodomain mediates NK cell activation at the cell contact site in case 
of an aNKIS. 
Interestingly, Endt et al describe a basal recruitment of NKG2D into DRM fractions in 
absence of stimuli in some of their experiments and speculate for a higher lipid raft 
affinity of NKG2D compared to other raft-associated receptors [144]. We observed a 
similar effect in some experiments with NKG2D (data not shown). Indeed, the 
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NKG2D complex could result in a higher affinity towards lipid rafts in case of 
lubrication as compared to other receptors as 2B4, which could only harbor one 
lubricated transmembrane domain. Thus, NKG2D-containing nanodomains might 
coalesce more easily into detergent-resistant membrane domains. 
 
Overall our data predict the main molecular mechanism of NKG2D recruitment into 
lipid rafts to reside in its transmembrane domain. The exact nature of this mechanism 
has to be resolved in future work, which will have to clarify whether NKG2D is 
palmitoylated and/or whether the homodimer of NKG2D is lubricated, e.g. by the 
association with sphingolipids. 
 
4.2 Development of a Siglec-7 inhibitor  
The sialic acid-binding receptor Siglec-7 is highly involved in the modulation of the 
immune system and has been implicated in immune surveillance against cancer 
[104, 105, 210], viral infections [108, 109] as well as bacterial infections [110, 111]. 
Additionally, it plays potential roles in tolerance against cells without high amounts of 
inhibitory ligands for other receptors, like erythrocytes or neuronal tissues. 
The development of an inhibitor that can be of advantage for scientific as well as 
therapeutic approaches thus appears more and more reasonable.  
 
In this work we discovered an inhibitor for Siglec-7 by screening for receptor-ligand 
affinity in a RBC inhibition assay, employing the described ability of Siglec-7 to bind 
RBCs [87, 91]. By a stepwise modification, inhibitors with a >3000-fold higher affinity 
compared to that of unmodified sialic acid (tables 10-11) were obtained. We 
assessed the ability of the inhibitor (compound 118, table 11) to affect NK cell 
function in 51Cr release assays, but we could only observe functional effects in a 
fraction of the experiments. The lack of any effect of the inhibitor on K562 might be 
due to the high stimulation given by K562 to NK cells [211]. As activating and 
inhibitory signals in NK cells are integrated, a high activating stimulus by the K562 
might override a weak inhibitory signal by Siglec-7 and thus result in full activation of 
the NK cells. Therefore, the presence of an inhibitor might not be detectable in this 
setting.  
The fact that we only observed low effects in a fraction of the Mel1106 killing assays 
might be due to different underlying causes:  
According to the literature, Siglec-7 can occur in two isoforms: One isoform with a V-
set Ig-domain and one C2-set Ig-domain [87] and another isoform with a V-set Ig-
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domain and two C2-set Ig-domains [91]. The expression of both isoforms on NK cells 
cannot be excluded so far. Although the C2-set domains have some implication for 
the ligand binding by Siglec-7 [86], the specificity of the inhibitor should not be 
altered by such differences. In contrast, the size of extracellular domains of NK cell 
receptors was shown to influence the signal integration [212]. The kinetic segregation 
model [213] states, that at the contact site of cells, the size of receptors can influence 
their segregation from this site. For example, very big receptors are unable to remain 
in the narrow synaptic cleft and are segregated from it. Thus, Siglec-7 isoforms with 
differing sizes might be segregated differentially and affect the integration of 
inhibitory signal by this receptor. It remains to be elucidated whether different cell 
types express only one isoform and whether isoform expression is donor-specific.  
Binding of ligands on other cells by Siglec receptors is also dampened by their 
common cis interaction with ligands, which results in masking of the receptor [88]. 
Siglec receptors are capable to bind sialic acids on the same cell they are expressed 
on, resulting in cis interaction. Such binding decreases the capacity of a receptor to 
bind a ligand on a different cell, namely a trans interaction. Such cis masking might 
have decreased the potential interaction of Siglec-7 with ligands on the target cells; 
thereby abolishing Siglec-7 mediated inhibition [214]. However, cis masking was 
shown to be decreased after sialidase treatment or cell activation [88]. We 
exclusively used IL-2 stimulated NK cells in the 51Cr release assays. This might have 
influenced the cis masking of Siglec-7. Previous studies with different Siglec 
receptors used phorbol ester and calcium ionophore stimulation to induce activation-
mediated unmasking of the receptors [88] and it remains to be tested, whether the 
stimulation of NK cells with IL-2 alone is sufficient to induce unmasking in a similar 
fashion. A complete dependency on unmasking of the receptor is also unlikely, as 
studies described the trans interaction of Siglec-2 despite cis masking [215] and a 
Siglec-7-dependent inhibition of GD3-expressing target cells was detectable without 
prior sialidase-treatment [104]. These findings either imply that Siglecs can recognize 
trans ligands despite cis masking, which might involve the low affinity of most Siglec 
ligands and could be broken by high affinity ligands as GD3 on target cells. Or a 
fraction of Siglecs remains unmasked and able to bind trans ligands; the latter might 
be achieved by a segregated localization of Siglecs and cis-ligands in the plasma 
membrane. In fact, a segregation of Siglec-2 in certain membrane domains is known 
[83], though there are no such data for Siglec-7 yet. 
Our data are also dependent on the inhibitory potential of Siglec-7 on NK cells. In our 
assays our inhibitor did only cause weak increases in lysis, but this small change 
might just resemble the whole capacity of Siglec-7 to influence NK cell activation. So 
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far, the direct inhibitory potential of Siglec-7 has not been related to the inhibitory 
potential of other receptors on NK cells, as KIRs for example. Siglec-7 might be 
limited in its inhibitory potential on NK cells and therefore the inhibition of Siglec-7 
might not result in stronger effects.  
Additionally, the experimental setting applied in our assays might not fulfill the 
optimal conditions for the observation of Siglec-7-mediated inhibition. In contrast to 
K562, Mel1106 cells are less stimulatory and have a higher load of inhibitory ligands. 
Maybe a different combination of activating and inhibitory ligands on the target cell 
would be more suited for this task. The perfect condition would include an inhibition 
of NK cells by the target cells only dependent on Siglec-7 whereas the activating 
stimuli should be weak enough for Siglec-7 to influence the overall NK cell activation. 
Future screenings of target cells might result in a better model for the analysis of 
Siglec-7 inhibitors.  
Finally, although our inhibitor is >3000-fold more potent than the unmodified sialic 
acid, the affinity of the inhibitor might still be insufficient to cause a potent effect on 
the inhibition mediated by Siglec-7 in this experimental setup. Therefore, the further 
improvement of the inhibitor remains an important focus of future work. 
 
The effects observed might in addition be caused by Siglec-7 independent 
mechanisms: As was shown in several studies so far, all CD33-related Siglecs and 
especially Siglec-7 and Siglec-9 are highly homologous and mainly differ in their 
ligand-binding V-set Ig-domain [80]. This homology between Siglec-7 and Siglec-9 is 
so high that the exchange of only a few amino acids in the C-C loop of the V-set Ig-
domain was sufficient to completely exchange ligand specificities of the two 
receptors [95]. In addition, previous ligand screening studies for Siglec-7 and Siglec-
9 showed certain redundancies in specificity, e.g. against α2,3- and α2,6-sialyl 
residues [95, 96]. Therefore, the effect observed in the killing assays could also be 
due to a Siglec-9 effect. This possibility appears unlikely though. First, on NK cells, 
Siglec-7 is more abundant than Siglec-9 ([87, 91-94] and our data). Second, the 
specificity of the inhibitor towards Siglec-7 is higher than for Siglec-9.  
According to our data, side effects of toxicity mediated by the inhibitor seem unlikely 
as well. The possibility of a drastic effect caused by the Siglec-7 inhibitor in such a 
killing assay stays a matter of debate: Although the structure of Siglec-7 has been 
well established since its discovery and inhibitory function of Siglec-7 has been 
shown [90, 104], the signaling after receptor ligation remains less well understood. 
According to the presence of a membrane-proximal ITIM in the Siglec receptor, a 
similar role as with other inhibitory receptors on NK cells was assumed. Indeed, it 
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was shown that Siglec-7 is able to recruit the tyrosine phosphatases SHP-1 and 
SHP-2 upon cross-linking [102], although to a lower extent than other receptors 
[216]. However, a second signaling motif is present membrane-distal to the ITIM, 
which was assumed to be an ITSM in early studies but was recognized to be a 
distinct ITIM-like motif later on [83, 217]. The exact function of this ITIM-like motif still 
remains unknown, apart from the fact that mutation of the membrane proximal ITIM 
motif abolishes SHP-1 association but not SHP-2 association with the membrane-
distal ITIM-like motif [102]. In another study, Siglec-7 was targeted by the 
‘Suppressor of cytokine signaling 3’ (SOCS3) for degradation once phosphorylated. 
SOCS3 belongs to a family of negative feedback proteins that attenuate cytokine-
induced signals. The common mechanism causes the ubiquitination of the signaling 
molecules and results in their degradation. Siglec-7 degradation occurred in an 
unusual mechanism degrading SOCS3 as well in the process [218]. Siglec-7 was 
even shown to mediate an non-apoptotic cell death without the involvement of the 
known signaling motifs [219]. These data show homologies to the inhibitory pathways 
of other inhibitory receptors on NK cells, but several discrepancies remain. 
Additionally, all these signaling studies were performed in model cell lines distinct 
from primary NK cells and therefore exact statements about the signaling processes 
downstream of Siglec-7 triggering should be regarded with care. Taken all these 
together, the exact regulation of Siglec-7 is not yet unraveled and therefore, its 
ligation and the inhibition of this ligation with an inhibitor might result in yet 
ambiguous data.  
 
Overall, our inhibitor effectively blocks Siglec-7 ligand interaction and is the first 
inhibitor able to modulate the activity of human NK cells. This study hopefully will 
promote the further development of Siglec inhibitors by providing information about 
the structural requirements of a Siglec-7 inhibitor. 
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In conclusion, this study further unraveled the molecular bases of lipid raft 
recruitment of the SLAM-related receptor 2B4 and the C-type lectin-like receptor 
NKG2D. Both of these receptors are crucially dependent on the structure of their 
transmembrane domain, but independent from signal transduction, for their 
localization into lipid rafts after ligation. In case of 2B4, the receptor is especially 
dependent on a CxC motif at the cytoplasmic side of the transmembrane domain and 
to a lesser extent dependent on the amino acids at the luminal side of 
transmembrane domain. These findings give profound information about the possible 
mechanisms leading to lipid raft recruitment and will enable a more specific analysis 
of these mechanisms. 
Additionally, this study led to the development of the first specific Siglec-7 inhibitor 
with the potential to affect the activity of human NK cells. This outcome will aid in the 
future development of scientific and therapeutic tools in the field of Siglec research. 
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ADCC Antibody-dependent cellular cytotoxicity 
AICL Activation induced C-type lectin 
ARG Arginine 
BSA Bovine serum albumin 
CD Cluster of differentiation 
Dap10 DNAX-activating protein of 10 kDa 
Dap12 DNAX-activating protein of 12 kDa 
DC Dendritic cell 
DMSO Dimethyl sulfoxide 
DRM Detergent-resistant membrane 
E. coli Escherichia coli 
ERM Ezrin, radixin, moesin 
E:T ratio Effector to target ratio 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
Fc Fragment crystallizable 
GD3 Disialoganglioside 3 
GEF Guanine nucleotide exchange factor 
GM1 Monosialoganglioside 1 
GPI Glycosylphosphatidylinositol 
h2B4 Human 2B4 
HA Hemagglutinin 
Ig Immunoglobulin 
IgG Immunoglobulin G 
IL Interleukin 
IP Immunoprecipitation 
IS Immunological synapse 
ITAM Immunoreceptor tyrosine-based activation motif 
ITIM Immunoreceptor tyrosine-based inhibition motif 
ITSM Immunoreceptor tyrosine-based switch motif 
KACL Keratinocyte-associated C-type lectin 
kDa Kilo Dalton 
KIR Killer cell Ig-like receptor 
LAK cell Lymphokine-activated killer cell 
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LAT Linker for activation of T cells 
LILR Leukocyte Ig-like receptor 
LSM Lymphocyte separation medium 
LYS Lysine 
m2B4 Murine 2B4 
MßCD Methyl-ß-cyclodextrin 
MFI Mean fluorescence intensity 
MHC Major histocompatibility complex 
MIC MHC class-I polypeptide-related chain 
min Minutes 
MTOC Microtubule organizing center 
NCR Natural cytotoxicity receptor 
NEAA Non-essential amino acids 
NK cell Natural killer cell 
NKIS NK cell immunological synapse 
PBL Peripheral blood lymphocytes 
PBMC Peripheral blood mononuclear cell 
PE Phycoerythrin 
PHA-P Phytohemagglutinin 
PI3K Phosphatidyl-inositol-3-kinase 
PLC Phospholipase C 
PVDF Polyvinylidene fluoride 
RBC Red blood cell 
rIP Relative inhibitory potential 
SAP SLAM-associated protein 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
Siglec Sialic acid-binding Ig-like lectins 
SLAM Signaling lymphocyte activation molecule 
SOCS3 Suppressor of cytokine signaling 3 
SRR SLAM-related receptor 
SYK Spleen tyrosine kinase 
TYR Tyrosine 
ULBP UL16-binding protein 
WB Western blot 
wt wildtype 
106   Abbreviations 
XLP X-linked lymphoproliferative disease 
x-link Cross-link 
ZAP-70 70 kDa zeta-chain associated protein 
 
